

518 Rec'd PCT/US 02 AUG 2001

Form PTO-1390 (Modified)  
(REV. 12-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

U.S. PATENT AND TRADEMARK OFFICE DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

RU-0115

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/744,002

INTERNATIONAL APPLICATION NO.  
**PCT/US99/16417**

INTERNATIONAL FILING DATE  
**21 July 1999**

PRIORITY DATE CLAIMED  
**21 July 1998**

**TITLE OF INVENTION**

**Linking Gene Sequence to Gene Function by Three Dimensional (3D) Protein Structure  
Determination**

**APPLICANT(S) FOR DO/EO/US**

**ANDERSON, Stephen et al.**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
- ☐ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A copy of the International Search Report (PCT/ISA/210).

**Items 13 to 20 below concern document(s) or information included:**

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with
20. ☐ A second copy of the published international application under 35 U.
21. ☐ A second copy of the English language translation of the international
22. ☐ Certificate of Mailing by Express Mail
23. ☐ Other items or information:

"Express Mail" Label No. **EL750774308US**  
Date of Deposit **August 2, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret  
Typed Name: Deborah Ehret

- 1) Notification of Missing Requirements;
- 2) Response to Notice to File Missing Parts and Petition for Extension of Time;
- 3) Return post card

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.492(a)(1)-(5)) <b>09/744002</b>	INTERNATIONAL APPLICATION NO. <b>PCT/US99/16417</b>	ATTORNEY'S DOCKET NUMBER <b>RU-0115</b>
---	--	--

21. The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</b>				<b>CALCULATIONS PTO USE ONLY</b>	
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1,000.00</b>					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$860.00</b>					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$710.00</b>					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$690.00</b>					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b>					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$860.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				<b>\$0.00</b>	
<b>CLAIMS</b>	<b>NUMBER FILED</b>	<b>NUMBER EXTRA</b>	<b>RATE</b>		
Total claims	13 - 20 =	0	x \$18.00	<b>\$0.00</b>	
Independent claims	3 - 3 =	0	x \$80.00	<b>\$0.00</b>	
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$860.00</b>	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input checked="" type="checkbox"/>				<b>\$430.00</b>	
<b>SUBTOTAL =</b>				<b>\$430.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				<b>\$0.00</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$430.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$430.00</b>	
				<b>Amount to be refunded</b>	\$
				<b>charged</b>	\$

☐ A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.  
 Adjustment date: 05/22/2001 AYILMAZ  
 04/20/2001 AYILMAZ 00000015 501619  
 01 FC:557 ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **50-1619** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

**SEND ALL CORRESPONDENCE TO:**

04/20/2001 AYILMAZ 00000015 501619 09744002  
 01 FC:557  
 Licata & Tyrrell P.C.  
 66 E. Main Street  
 Marlton, New Jersey 08053  
 Telephone: (856) 810-1515  
 Facsimile: (856) 810-1454

*Jane Massey Licata*  
 SIGNATURE  
**LICATA, Jane Massey**  
 NAME  
**32,257**  
 REGISTRATION NUMBER  
**18 January 2001**  
 DATE

<b>VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION</b>			Docket No. RU-0115
Serial No. Not Yet Assigned	Filing Date Herewith	Patent No.	Issue Date
Applicant/ <b>ANDERSON ET AL.</b> Patentee:			<b>JAN 15 2001</b>
Invention: <b>LINKING GENE SEQUENCE TO GENE FUNCTION BY THREE DIMENSIONAL (3D) PROTEIN STRUCTURE DETERMINATION</b>			
<p>I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:</p> <p>NAME OF ORGANIZATION: <u>Rutgers, the State University</u></p> <p>ADDRESS OF ORGANIZATION: <u>Old Queens Building</u> <u>Somerset and George Streets</u> <u>New Brunswick, New Jersey</u></p> <p>TYPE OF NONPROFIT ORGANIZATION:</p> <p><input checked="" type="checkbox"/> University or other Institute of Higher Education</p> <p><input type="checkbox"/> Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))</p> <p><input type="checkbox"/> Nonprofit Scientific or Educational under Statute of State of The United States of America Name of State: _____ Citation of Statute: _____</p> <p><input type="checkbox"/> Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America</p> <p><input type="checkbox"/> Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America Name of State: _____ Citation of Statute: _____</p> <p>I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:</p> <p><input checked="" type="checkbox"/> the specification to be filed herewith.</p> <p><input type="checkbox"/> the application identified above.</p> <p><input type="checkbox"/> the patent identified above.</p> <p>I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.</p> <p>If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).</p>			

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern or organization exists.  
☐ each such person, concern or organization is listed below.

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME

ADDRESS

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:


TITLE IN ORGANIZATION:

ADDRESS OF PERSON SIGNING: Rutgers, the State University  
Olds Queens Building  
Somerset and George Streets  
New Brunswick, New Jersey

SIGNATURE:



DATE:



Rec'd PCT/PTO 30 JUL 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5/a

Attorney Docket No.: RU-0115  
Inventors: Anderson et al.  
Serial No. 09/744,002  
Filing Date: January 18, 2001  
Examiner: Not yet assigned.  
Group Art Unit: Not yet assigned.



Title: Linking Gene Sequence to Gene Function by  
Three Dimensional (3D) Protein Structure  
Determination

"Express Mail" Label No. EL 792267219 US  
Date of Deposit - July 30, 2001

I hereby certify that this paper is being deposited with  
the United States Postal Service "Express Mail Post Office  
to Addressee" service under 37 CFR 1.10 on the date  
indicated above and is addressed to the Assistant Commissioner for  
Patents, Washington, D.C. 20231.

By Kathleen A. Tyrrell  
Kathleen A. Tyrrell, Reg. No. 38,350

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Preliminary Amendment to Specification

Please enter the following amendment into the record.

In the Specification:

Please replace the paragraph at page 8, lines 28-29, as  
follows:

--Figure 8A provides an illustration of information derived  
from triple resonance data sets of a region of recombinant CspA

09744002 080301

Attorney Docket No.: RU-0115  
Inventors: Anderson et al.  
Serial No.: 09/744,002  
Filing Date: January 18, 2001  
Page 2


(SEQ ID NO:1) used for establishing intraresidue and sequential correlation of spin systems.--

#### REMARKS

In response to the Notice to Comply dated May 30, 2001, Applicants are amending the specification to include a sequence identifier, namely SEQ ID NO:1, for the region of recombinant CspA (SEQ ID NO:1) depicted in Figure 8A. No new matter has been entered by this amendment. Entry is therefore respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with Markings to Show Changes Made."

Respectfully submitted,



KATHLEEN A. TYRRELL  
Registration No. 38,350

Date: July 30, 2001

LICATA & TYRRELL P.C.  
66 E. Main Street  
Marlton, NJ 08053

(856) 810-1515

09/744,002-030201

Attorney Docket No.: RU-0115  
Inventors: Anderson et al.  
Serial No.: 09/744,002  
Filing Date: January 18, 2001  
Page 3

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The paragraph at page 8, lines 28-29, have been amended as follows:

Figure 8A provides an illustration of information derived from triple resonance data sets of a region of recombinant CspA (SEQ ID NO:1) used for establishing intraresidue and sequential correlation of spin systems.

09/744,002-000001

## TITLE OF THE INVENTION

**LINKING GENE SEQUENCE TO GENE FUNCTION**  
**BY THREE DIMENSIONAL (3D) PROTEIN**  
**STRUCTURE DETERMINATION**

## 5 CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of Provisional Patent Application No. 60/093,641 (filed July 21, 1998) and of U.S. Patent Application Serial No. 09/181,601 (filed October 29, 1998), which claims priority under 35 U.S.C. § 119(e) to Provisional Patent Application No. 60/063,679 (filed on October 29, 1997).

## 10 FIELD OF THE INVENTION

The present invention pertains to methods for elucidating the function of proteins and protein domains by examination of their three dimensional structure, and more specifically, to the use of bioinformatics, molecular biology, and nuclear magnetic resonance (NMR) tools to enable the rapid and automated determination of functions, as  
15 a means of genome analysis. The present invention further pertains to an integrated system for elucidating the function of proteins and protein domains by examining their three dimensional structure.

## BACKGROUND OF THE INVENTION

One of the most powerful ways of identifying the biochemical and medical  
20 function of a gene product is to determine its three-dimensional structure. Although there are numerous examples in which the primary (i.e., linear) structure of a protein has provided key clues to its biochemical function, three dimensional (3D) structure determination is considered to be more definitive at establishing biochemical function. The process of elucidating the 3D structure of large molecules, such as proteins is  
25 generally thought of as slow and expensive.

In the past, most drugs were discovered by screening proprietary chemicals with animal models or receptor libraries. Today, this approach is being replaced by "combinatorial chemistry" and "rational drug design". These are the primary methods



being used in the development of, for example, drugs targeted at the enzymes of the human AIDS virus.

What limits the drug discovery process today is not screening or medicinal chemistry but the rate that the approximately 100,000 proteins in the human body can be identified and prioritized as potential drug targets. Of particular significance for the pharmaceutical industry are the emerging disciplines of bioinformatics and functional genomics. Application of technologies developed in these areas will allow companies to identify, in the next decade, the bulk of the most significant new drug targets. It has been estimated that about 10,000 genes from the human genome are of potential value in human medicine, but only a few percent of these genes have been isolated so far. However, it is reported that by the year 2005 the raw sequence data for all of these genes will have been determined by the Human Genome Project (HGP).

## I. PROTEIN STRUCTURE

It is a generally accepted principle of biology that a protein's primary sequence is the main determinant of its tertiary structure. Anfinsen, *Science* 181:223-230 (1973); Anfinsen and Scheraga, *Adv. Prot. Chem.* 29:205-300 (1975); and Baldwin, *Ann. Rev. Biochem.* 44:453-475 (1975). For over a decade, researchers have been studying the theoretical and practical aspects of the folding of recombinant proteins.

For example, the "genetics" of protein folding using mutants of bovine pancreatic trypsin inhibitor (BPTI) has been studied. Mutants of BPTI were prepared in which several cysteine residues were replaced by alanine or threonine residues. These mutants were then expressed in a heterologous *E. coli* expression system. Although these mutants were found to fold into the proper conformation, the rate of the mutant folding was somewhat slower than that exhibited by wild-type BPTI. Marks *et al.*, *Science* 325:1370-1373 (1987).

Ma *et al.* have also studied the genetics of protein folding using mutants of BPTI. Ma *et al.*, *Biochemistry* 36:3728-3736 (1997). The model system described by Ma *et al.* predicts that a "rearrangement" mechanism to form buried disulfides at a late stage in the folding reaction may be a common feature of redox folding pathways for surface disulfide-containing proteins of high stability.

Nilsson *et al.* have reported that factors, such as peptidyl prolyl isomerase, protein disulfide isomerase, thioredoxin, and Sec B, may interact with the unfolded forms of specific classes of proteins, while members of the hsp70/DnaK and

-3-

hsp60/GroEL molecular chaperone families may play a more general role in protein folding. Nilsson *et al.*, *Ann. Rev. Microbiol.* 45:607-635 (1991). Nilsson *et al.* further disclose that intrinsic folding rates, or even translation rates, of nascent proteins may be optimized by natural selection. Secretion, proteolysis and aggregation are other *in vivo* processes that depend greatly in the folding behavior of a given protein. Thus, protein folding involves an interplay between the intrinsic biophysical properties of a protein, in both its folded and unfolded states, and various accessory proteins that aid in the process.

Proteins are generally composed of one or more autonomously-folding units known as domains. Kim *et al.*, *Ann. Rev. Biochem.* 59:631-660 (1990); Nilsson *et al.*, *Ann. Rev. Microbiol.* 45:607-635 (1991). Multidomain proteins in higher organisms are encoded by genes containing multiple exons. Combinatorial shuffling of exons during evolution has produced novel proteins with different domain arrangements having different associated functions. This is thought to have greatly increased the ability of higher organisms to respond to environmental challenges because, via recombinational events, it has enabled genomes to readily add, subtract, or rearrange discrete functionalities within a given protein. Patthy, *Cell* 41:657-663 (1985); Patthy, *Curr. Opin. Struct. Bio.* 4:383-392 (1994); and Long *et al.*, *Science* 92:12495-12499 (1995).

## II. INTERPRETATION OF A PROTEIN STRUCTURE

Several methods have been used to elucidate the 3D structure of a given protein molecule. Chiefly, these methods are X-ray crystallography and Nuclear Magnetic Resonance (NMR).

### A. X-Ray Crystallography

X-ray crystallography is a technique that directly images molecules. A crystal of the molecule to be visualized is exposed to a collimated beam of monochromatic X-rays and the consequent diffraction pattern is recorded on a photographic film or by a radiation counter. The intensities of the diffraction maxima are then used to construct mathematically the three-dimensional image of the crystal structure. X-rays interact almost exclusively with the electrons in the matter and not the nuclei.

The spacing of atoms in a crystal lattice can be determined by measuring the angle and intensities at which a beam of X-rays of a given wave length is diffracted by the electron shells surrounding the atoms. Operationally, there are several steps in X-

ray structural analysis. The amount of information obtained depends on the degree of structural order in the sample. Blundell *et al.* provide an advanced treatment of the principles of protein X-ray crystallography. Blundell *et al.*, *Protein Crystallography*, Academic Press (1976), herein incorporated by reference. Likewise, Wyckoff *et al.* provide a series of articles on the theory and practice of X-ray crystallography. Wyckoff *et al.* (Eds.), *Methods Enzymol.* 114: 330-386 (1985), herein incorporated by reference.

### B. Nuclear Magnetic Resonance (NMR)

The classical approach for the analysis of NMR resonance assignments was first outlined by Wüthrich, Wagner and co-workers. Wüthrich, "NMR of proteins and nucleic acids" Wiley, New York, New York (1986); Wüthrich, *Science* 243:45-50 (1989); Billeter *et al.*, *J. Mol. Biol.* 155:321-346 (1982), all of which are herein incorporated by reference. For a general review of protein determination in solution by nuclear magnetic resonance spectroscopy, see Wüthrich, *Science* 243:45-50 (1989). See also, Billeter *et al.*, *J. Mol. Biol.* 155:321-346 (1982).

Wüthrich's classical approach can be briefly summarized in the following seven steps:

- Step 1: Identification of individual resonances associated with each spin system, and designation of key atom types (e.g.,  $H^N$ ,  $H^\alpha$ , N,  $C^\alpha$ ,  $C^\beta$ , etc.).
- Step 2: Classification of each identified spin system with respect to one or more possible amino acid residue type(s).
- Step 3: Identification of possible sequential relations between spin systems using inter-residue NOESY or triple-resonance data.
- Step 4: Unique mapping of strings of sequentially-connected spin systems to segments of the amino acid sequence, thus establishing "sequence specific assignments."
- Step 5: Extension of assignments to resonances of peripheral side-chain nuclei in each spin system, and determination of stereospecific assignments.
- Step 6: Generation of distance constraints using assigned resonance frequencies to interpret NOESY, scalar-coupling, and

-5-

hydrogen/deuterium-exchange data in terms of "sequence-specific distance constraints."

Step 7: Structure generation using these constraints.

Automated implementation of these methods have made use of exhaustive  
5 search, constraint satisfaction, heuristic best-fit or branch-and-bound limited search, genetic, neural net, pseudoenergy minimization, and simulated annealing satisfaction. Billeter *et al.*, *J. Magn. Resonance* 76:400-415 (1988); Zimmerman *et al.*, In: *Proceedings of the First International Conference of Intelligent Systems for Molecular Biology*, Washington: AAAS Press (1994); Zimmerman *et al.*, *J. Biomol. NMR* 4:241-  
10 256 (1994); Zimmerman *et al.*, *Curr. Opin. Struct. Bio.* 5:664-673 (1995); and Zimmerman *et al.*, *J. Mol. Bio.* 269:592-610 (1997).

Under traditional methodology, before a given protein is studied at the 3D level, the researcher had already obtained detailed experimental information regarding the protein's function and characteristics. The 3D structure is typically the last of many  
15 experiments performed over many years of study. The 3D structure information is then used to refine the researcher's understanding of the given protein. Thus, under traditional methodology, it is very rare that the 3D structure of a given protein is determined before its biochemical function has been determined by other methods.

The present invention represents a paradigm shift in methodology because the  
20 researcher would first determine the 3D structure of a protein of unknown function and then use this structure to gain clues as to its function, which would be subsequently validated by appropriate biochemical assays.

## SUMMARY OF THE INVENTION

The present invention describes an integrated system for rapid determination of  
25 the three-dimensional structures of proteins and protein domains and application of this technology in a high-throughput analysis of human and other genomes for drug discovery purposes.

The "structure-function analysis engine" described herein has the potential to  
30 discover the functions of novel genes identified in the human and other genomes faster than existing genetic or purely computational bioinformatics methods.

The present invention employs:

1. Bioinformatics methods, including the analysis of exon-exon phases and other methods for segmenting or "parsing" DNA sequences of novel genes into domain-encoding regions:
- 5 2. Robust and general "domain trapping" methods for producing correctly-folded recombinant protein domains of novel biomedically-important human disease gene products:
3. Robust and general methods for high level expression and isotopic enrichment of these domains for NMR and X-ray crystallographic studies:
- 10 4. Screening methods to identify protein domain constructs that exhibit the properties required for structural analysis by NMR or X-ray crystallography:
5. Computer software, NMR pulse sequences, and related NMR technologies that provide fully automated analysis of protein structures from NMR data:
- 15 6. NMR spectroscopy methods for determining 3D structures of these domains:
7. Improved methods for mapping new domain structures to proteins in the Protein Data Bank that have similar structures and biochemical functions:
- 20 8. A relational data base of the empirical properties of expressed domains for organizing and integrating the biophysical and biological information derived from these studies, as well as methods for making such relational data bases; and
- 25 9. A method for integrating all of the above into a large-scale, high-throughput macromolecular "structure-function analysis engine," and the application this "structure-function analysis engine" to the discovery of biochemical functions of hundreds of genes from humans and human pathogens.
- 30 The specific biomedical gene targets that this technology can be used to develop include:
  1. Domains from the human Alzheimer's  $\beta$  peptide precursor protein (APP).

-7-

2. Domains from other proteins genetically implicated in neoplastic, metabolic, neurodegenerative, cardiovascular, psychiatric and inflammatory disorders.
3. Domains from proteins associated with infectious agents (e.g., bacteria, fungi and viruses).

The present invention provides a high-throughput method for determining a biochemical function of a protein or polypeptide domain of unknown function comprising: (A) identifying a putative polypeptide domain that properly folds into a stable polypeptide domain, the stable polypeptide having a defined three dimensional structure; (B) determining three dimensional structure of the stable polypeptide domain; (C) comparing the determined three dimensional structure of the stable polypeptide domain to known three-dimensional structures in a protein data bank, wherein the comparison identifies known structures within the protein data bank that are homologous to the determined three dimensional structure; and (D) correlating a biochemical function corresponding to the identified homologous structure to a biochemical function for the stable polypeptide domain.

The present invention further provides an integrated system for rapid determination of a biochemical function of a protein or protein domain of unknown function: (A) a first computer algorithm capable of parsing the target polynucleotide into at least one putative domain encoding region; (B) a designated lab for expressing the putative domain; (C) an NMR spectrometer for determining individual spin resonances of amino acids of the putative domain; (D) a data collection device capable of collecting NMR spectral data, wherein the data collection device is operatively coupled to the NMR spectrometer; (E) at least one computer; (F) a second computer algorithm capable of assigning individual spin resonances to individual amino acids of a polypeptide; (G) a third computer algorithm capable of determining tertiary structure of a polypeptide, wherein the polypeptide has had resonances assigned to individual amino acids of the polypeptide; (H) a database, wherein stored within the database is information about the structure and function of known proteins and determined proteins; and (I) a fourth computer algorithm capable of determining 3D structure homology between the determined three-dimensional structure of a polypeptide of unknown function to three-dimensional structure of a protein of known function, wherein the protein of known structure is stored within the protein database.

The present invention further provides a high-throughput method for determining a biochemical function of a polypeptide of unknown function encoded by a target polynucleotide comprising the steps: (A) identifying at least one putative polypeptide domain encoding region of the target polynucleotide ("parsing"); (B) expressing the putative polypeptide domain; (C) determining whether the expressed putative polypeptide domain forms a stable polypeptide domain having a defined three dimensional structure ("trapping"); (D) determining the three dimensional structure of the stable polypeptide domain; (E) comparing the determined three dimensional structure of the stable polypeptide domain to known three dimensional structures in a Protein Data Bank to determine whether any such known structures are homologous to the determined structure; and (F) correlating a biochemical function corresponding to the homologous structure to a biochemical function for the stable polypeptide domain.

#### BRIEF DESCRIPTION OF THE FIGURES

Figure 1 provides a flow chart of the high-throughput structure/function analysis system of the present invention.

Figure 2A provides the far UV circular dichroism spectra of the purified recombinant APP NTD2-3 domain. Figure 2B provides the near UV circular dichroism spectra of the purified recombinant APP NTD2-3 domain.

Figure 3 provides a NMR spectra of the purified recombinant APP NTD2-3.

Figure 4 provides a hydrogen-deuterium exchange time course for the purified recombinant APP NTD2-3.

Figure 5 provides the results of a cooperative thermal unfolding experiment of the purified recombinant APP NTD2-3.

Figure 6 provides the results of the NMR  $^{15}\text{N}$ - $^1\text{H}$  heteronuclear single quantum coherence (HSQC) spectral analysis of the NTD2-3 domain collected on a Varian Unity 500 spectrometer.

Figure 7 provides the 2D  $^{15}\text{N}$ - $^1\text{H}$  HSQC spectrum of CspA at pH 6.0 and 30°C.

Figure 8A provides an illustration of information derived from triple resonance data sets used for establishing intrasidue and sequential correlations of spin systems.

Figure 8B provides an illustration of NMR data used to identify structural elements in CspA. Slowly exchanging backbone amides ( $t_{1/2} > 3$  min at pH 6.0 and 30°C) are indicated by filled circles ( $t_{1/2} < 30$  min) or stars ( $t_{1/2} > 30$  min.). Values of  $^3J(\text{H}^{\text{N}}-\text{H}^{\alpha})$  coupling constants are indicated by vertical bars; filled bars indicate that the

data provided a useful estimate ( $\pm 0.5$ Hz) of the corresponding coupling constant, while open bars indicate that the experimental data provide only an upper bound on its value. Values of conformation-dependent secondary shifts  $\Delta\delta C^\alpha$  and  $\Delta\delta C^\beta$  are plotted with solid bars. The locations of the five  $\beta$ -strands are indicated with arrows.

5 Figure 9 provides a flow chart of a NOESY\_ASSIGN Process of the present invention.

Figures 10A and B provide the 3D structure of the Zdom protein.

Figures 11, 12 and 13 provide results of an automated assignment analysis for the Zdom protein.

10 Figures 14, 15 and 16 provide results of a manual assignment analysis for the Zdom protein.

Figure 17 provides the 3D structure of the Cspa protein.

Figures 18, 19 and 20 provide results of an automated assignment analysis for the Cspa protein.

15 Figures 21, 22, and 23 provide results of a manual assignment analysis for the Cspa protein.

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

One of the best clues to a protein's function is its structure. The present invention describes a structure-based bioinformatics platform to be used in "functional  
20 genomics" analyses of the torrent of DNA sequence data emerging from the international HGP. This technology will allow for the isolation of novel biopharmaceuticals and/or drug targets from gene sequence information with an efficiency that is far beyond present day capabilities. By developing extremely fast yet rigorous technologies for macromolecular structure determination, it is possible to  
25 convert the stream of one-dimensional DNA sequence information emerging from human genome research efforts into 3D protein structures. This 3D structural information can then be used to map these human gene products to protein families with similar biochemical functions.

30 The present invention describes a "drug discovery search engine" that allows human genetic and genomic data to be smoothly interfaced with proven rational drug design and combinatorial chemistry approaches. The technology described herein enables determination of the structures for virtually the entire complement of human protein domains, encoded in the approximately 100,000 human genes.



## I. STRUCTURE SUGGESTS FUNCTION

It is a tenet of modern structural biology that structure suggests function: a given protein "fold" tends to be used over and over again in nature for a restricted set of biological functions. Knowledge of the structure of a new protein often reveals kinship to a family of other proteins with already known functions, and thus provides strong clues regarding the biochemical function of the protein at hand. Holm *et al.*, *Science* 273:595-603 (1996); Bork *et al.*, *Curr. Opin. Struct. Bio.* 4:393-403 (1994); Brenner *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 95:6073-6078 (1998), all of which are herein incorporated by reference. This kinship relationship is a natural manifestation of the fact that families of protein molecules have evolved from a common ancestral molecule, and that in the course of this evolution the 3D structure is largely preserved while new, though chemically related, biochemical functions are adopted. This is precisely the reasoning behind the assigning of "expressed sequence tag" (EST) sequences to known protein families using one-dimensional sequence comparisons.

Evolution generally acts to conserve 3D structures rather than the amino acid sequences of proteins. For this reason, proteins have often evolved over time so that their sequences exhibit no obvious similarity while their structures remain highly homologous. In practical terms, this means that simple sequence comparisons overlook many -- and perhaps even most -- instances of protein-protein relatedness. However, this relatedness, with all of its functional implications, can easily be identified by 3D structure comparisons.

The multidomain nature of many mammalian proteins makes them more difficult to express in recombinant form and also impedes their structure determination by X-ray crystallography or NMR. The expression and structure determination of an isolated domain is, in contrast, less problematical. Since an isolated domain comprises one or more discrete functional units in a protein, knowing structure-function information about a given individual domain in a multicomponent protein generally provides key information that can be used to proceed with drug development on the full-length protein. The "domain trapping" methods of the present invention generate many novel gene products suitable for structural analysis by NMR spectroscopy and X-ray crystallography.

Recent developments in the areas of high-level protein expression technology, X-ray crystallography, heteronuclear NMR spectroscopy, and artificial intelligence (AI)-based structural analysis software, have dramatically improved the speed and lowered

-11-

the cost of protein structure determination. Estimates of the total number of human genes in the genome (approximately  $10^5$ ) contrast dramatically with estimates of the total number of protein folds in nature (approximately  $10^3$ ), and it has been estimated that one-third to one-half of these folds have already been described. Chothia *et al.*,  
5 *Nature* 357:543-544 (1992). Simple statistics imply that many new gene products will exhibit structures that map to existing fold classes associated with proteins of known biochemical function. Thus, the harvest of functional information about new human genes from this approach will be immediate.

## 10 II. DESIGN OF A HIGH-THROUGHPUT SYSTEM FOR DETERMINING PROTEIN STRUCTURES AND FUNCTIONS

Figure 1 provides a flow chart of the high-throughput structure/function analysis used in the present invention for analyzing human and pathogen gene products. This flow chart outlines the general methods of the present invention. Each sub-step of the  
15 present invention is outlined in detail below. It is to be understood that the hardware disclosed herein can be or is operatively linked to one or more computers.

### A. Approaches For Identifying Novel Protein Domains

The present invention provides a method for predicting the location of domains and domain boundaries within a given DNA sequence. Under one embodiment, this is  
20 accomplished through a knowledge based application which segments or "parses" genomic or cDNA sequences of genes into domain encoding sequences. Under another embodiment, the knowledge based application of the present invention can also segment or "parse" mRNA sequences into domain encoding sequences. Preferably, the knowledge based application of the present invention is encoded within a computer  
25 algorithm software application. Preferably, this expert system applies rules developed on a set of experimentally-verified DNA sequence/protein domain comparisons that have been compiled from public sequence and protein structure databases. Thus, for a novel gene sequence, this expert system generates the predicted domains and/or domain boundaries which are then used to create domain-specific expression constructs.

30 Under one of the preferred embodiments, the gene sequence is parsed by the exon phase rule. Exon termini (5'- or 3') that begin or end within protein coding regions can be classified according to their "phase": an exon terminus that falls between two codons is called a "phase 0" terminus; an exon terminus that starts or stops after the first

-12-

nucleotide in the codon is called a "phase 1" terminus; and an exon terminus that starts or stops after the second nucleotide in the codon is called a "phase 2" terminus. For example, where ("\*") marks the positions of an exon-exon junction--

5                   Phase 0:       \*

                  5' ... -A-T-G-G-G-A-C-T-C- ... 3'

                  ... - Met - Gly - Leu - ...

                  Phase 1:       \*

10                  5' ... -A-T-G-G-G-A-C-T-C- ... 3'

                  ... - Met - Gly - Leu - ...

                  Phase 2:       \*

15                  5' ... -A-T-G-G-G-A-C-T-C- ... 3'

                  ... - Met - Gly - Leu - ...

20                  The genetic coding sequences for protein domains, which have been reported to have been "shuffled" between various genes during evolution, should be bounded by exon termini of the same phase (or by the N- or C-terminal ends of the holoprotein), otherwise insertion of these domains into a host gene would result in a frame-shift mutation in the downstream sequences upon splicing (Patthy, *Cell* 41:657-663 (1985); Patthy, *FEBS Letters* 214:1-7 (1987); Patthy, *Curr. Opin. Struct. Bio.* 4:383-392 (1994), all of which are herein incorporated by reference). Therefore, the domain encoding regions should be bounded on both sides by phase 0 exon termini, by phase 1 exon termini, or by phase 2 exon termini, but not by termini of different phases.

25                  As part of the mechanism of molecular evolution, structural and functional domains are mixed and matched between protein sequences through the processes of gene duplication and crossover. Accordingly, under one preferred embodiment domains are identified by looking for segments of gene sequences that are conserved across many genes from different organisms. Known domain families generally involve 50 -

30                  300 amino-acid long segments that are observed as portions of many different proteins. Bioinformatics algorithms capable of identifying these conserved segments, or gene-fragment clusters, in the data base of gene sequences have been reported. These algorithms can be used to identify candidate domain-encoding regions in novel gene

-13-

sequences. Gouzey *et al.*, *Trends Biochem. Sci.* 21:493 (1994), herein incorporated by reference.

Under a second preferred embodiment, domains from gene sequence data are identified through predictions of their interdomain boundaries. There is ample evidence  
5 from molecular evolution and cell biology studies that information regarding domain boundaries is embedded in the sequences of protein coding genes. Some reports have claimed that rare codon clusters, which cause ribosomal pausing during translation, are correlated with domain boundaries. Purvis *et al.*, *J. Mol. Biol.* 193:413-417 (1987); Nilsson *et al.*, *Ann. Rev. Microbiol.* 45:607-635 (1991); Thanaraj *et al.*, *Protein Sci.*  
10 5:1973-1983 (1996); Thanaraj *et al.*, *Protein Sci.* 5:1594-1612 (1996); and Guisez *et al.*, *J. Theor. Biol.* 162:243-252 (1993), all of which are herein incorporated by reference. Messenger RNA secondary structure have also been reported to play such a "punctuation" role during translation.

One embodiment of the present invention employs an algorithm that identifies  
15 such sequence features and compares these data with the actual domain sequences in the relational database of the present invention. The relational database of the present invention contains domain sequence information of known and determined protein domains. It is understood that the relational database of the present invention will expand over time such that each polypeptide domain determined using the methods of  
20 the present invention will be added to the relational database. Under this embodiment, it is possible to rigorously assess the reliability of these bioinformatics methods of domain prediction and, iteratively, modify the software to improve its reliability. Neural nets and genetic algorithms both can be used for deriving rules for domain boundaries from this knowledge base. This invention markedly accelerates productivity  
25 by greatly reducing the number of expression constructs that would have to be tested in order to correctly parse a novel gene sequence into its component domain sequences.

Under another embodiment, the solution structure of a protein or protein domain can be analyzed by a method that combines enzymatic proteolysis and matrix assisted laser desorption ionization mass spectrometry (Cohen *et al.*, *Protein Sci.* 4:1088-1099  
30 (1995), Seielstad *et al.*, *Biochem.* 34:12605-12615 (1995), both of which are incorporated by reference in their entirety). This method is capable of inferring structural information from determinations of protection against enzymatic proteolysis as governed by solvent accessibility and protein flexibility. Preferably, the proteolytic enzymes employed by this method include trypsin, chymotrypsin, thermolysin, and  
35 ASP-N endoprotease.

**B. "Domain Trapping": Expression And Biophysical Characterization Of Putative Recombinant Protein Domains**

With respect to genes of unknown function, the investigator, generally, does not have available an enzyme assay or other obvious activity-based means to assess the biochemical activity of a novel recombinant protein domain. The present invention has addresses this difficulty in a three-pronged manner. First, the present invention uses a reliable and high yield expression system for protein expression. For example, a secretion-based protein A fusion system that is one of the most tested and reliable methods known for producing correctly-folded recombinant proteins in the *E. coli* periplasm. Nilsson *et al.*, *Methods Enzymol.* 185:144-161 (1990), herein incorporated by reference. Alternatively, the pET plasmid expression system may be used. Studier *et al.*, *J. Mol. Bio.* 189:113-130 (1986), herein incorporated by reference. Second, the present invention uses a set of activity-independent biophysical criteria to assess whether the protein domain has properly folded. This set of criteria has been developed through extensive study of recombinantly-expressed protein folding mutants. Finally, based on the supposition that autonomous folding of the protein domain can be prevented due to too much or too little polypeptide sequence information, respectively, (Kim *et al.*, *Ann. Rev. Biochem.* 59:631-660 (1990); Nilsson *et al.*, *Ann. Rev. Microbiol.* 45:607-635 (1991), both of which are herein incorporated by reference), the present invention uses systematic strategies for identifying and trapping domains that enables it to use a combination of molecular biological and biophysical methods to experimentally parse any gene into its component domains. In other words, a polypeptide domain has a "defined three dimensional structure" when that polypeptide domain exhibits the activity-independent biophysical criteria of a properly folded domain.

Under one preferred embodiment, an activity-independent biophysical criteria used to assess the correctness of folding of a protein includes circular dichroism measurements. More preferably, characterization of an isolated domain of a protein is analyzed by circular dichroism measurements in the far UV. An ellipticity minimum at 222 nm is indicative of  $\alpha$ -helical secondary structure. Preferably, CD measurements at longer wavelengths are also determined (for a general review of CD and other methods, see Creighton, *Proteins: Structure and molecular properties*, 2nd Ed., W. H. Freeman & Co., New York, New York (1993, and related texts), herein incorporated by reference). A signal in the aromatic region around 280 nm is consistent with the presence of Trp, Tyr. and Phe chromophores in an ordered environment, such as would

-15-

be expected in the hydrophobic core of a folded protein. In general, assays for the affinity-purified expressed proteins that employ solely biophysical criteria have been designed based upon experience with the behavior of misfolded recombinant proteins.

It is preferable to further characterize the isolated domain by <sup>1</sup>H-NMR

- 5 spectroscopy. Preferably, the isolated domain is in a moderately concentrated solution (~100 μM). A high dispersion pattern of the proton resonance spectrum is reported to be characteristic of a well-folded polypeptide.

- A time-course of amide hydrogen-deuterium exchange measurements can also be performed on the isolated domain. From this, it is possible to observe whether  
10 backbone NH groups are significantly protected within the domain. Significant protection is an indication that the hydrogen-bonded secondary structure is stabilized by tertiary interactions, which is consistent with a well-folded domain structure.

- Finally, thermal denaturation experiments, monitored by intrinsic tryptophan fluorescence, can also be performed. These experiments are also capable of determining  
15 whether the isolated domain is a compact domain structure.

- In principle, this is a general strategy. Thus, it can be used to parse many genes in the human genome that encode proteins of unknown biochemical function into their component domains and express correctly-folded polypeptide for structure/function studies. This general strategy can be easily modified to provide a high-throughput  
20 method for validating candidate domains identified by the bioinformatics methods of the present invention. For a typical 10 - 30 kD protein domain, 500 or 600 MHz one-dimensional (1D) NMR spectra can be obtained in tens of minutes using only small quantities (~ 200 μg) of protein. Using a continuous flow NMR probe with a microcomputer-controlled chromatography pump and simple sample changer, it is  
25 possible to automatically screen 50 - 100 candidate domains per day for folded structure. Those candidate domains which exhibit chemical shift dispersion indicative of ordered domain structure can then be further validated using the other biophysical techniques described above. An NMR spectrometer suitable for use in the present invention is a Varian Unity 500 spectrometer.

30 **C. High Level Expression And Isotopic Enrichment**

Uniform biosynthetic enrichment with <sup>15</sup>N, <sup>13</sup>C and <sup>2</sup>H isotopes has been reported to be a prerequisite for the analysis of macromolecular structures by NMR spectroscopy. Some NMR strategies have also been reported to benefit from random

enrichment with  $^2\text{H}$  isotopes. The principal obstacle for isotope-enriched protein production in most recombinant production systems is the high cost of the enriched media components (e.g.  $^{13}\text{C}$ -glucose @ \$330/g), and the limiting possibilities for scale-up to controlled multi-liter fermenters. The less well-controlled conditions of shaker flask cultivations often result in lower protein production levels. The production of  $^{15}\text{N}$ -,  $^{13}\text{C}$ -, and/or  $^2\text{H}$ -enriched proteins thus requires an efficient system capable of providing high level production of the desired protein in small-scale bioreactors.

Under one preferred embodiment, the present invention employs a bacterial production system for  $^{15}\text{N}$ ,  $^{13}\text{C}$ -enriched recombinant proteins. Preferably, the bacterial production system is based on intracellular production of recombinant proteins in *E. coli* as fusions to an IgG-binding domain analogue, Z, derived from staphylococcal Protein A (Nilsson *et al.*, *Protein Eng.* 1:107-113 (1987); Altman *et al.*, *Protein Eng.* 4:593-600 (1991), both of which are herein incorporated by reference). In this system, transcription is initiated from the efficient promoter of the *E. coli trp* operon. This allows for efficient intracellular production of fusion proteins. These fusion proteins can then be purified by IgG affinity chromatography. Using this approach it is possible to achieve high-level (40 - 200 mg/L) production in defined minimal media of a number of isotope-enriched proteins (see, for example, Jansson *et al.*, *J. Biomol. NMR* 7:131-141 (1996)).

Under another preferred embodiment, the recombinant isotope-enriched domain protein may be produced using pET plasmid expression vectors (Studier *et al.*, *J. Mol. Biol.* 189:113-130 (1986), herein incorporated by reference) under the control of the T7 RNA polymerase promoter (see, for example, Newkirk *et al.*, *Proc. Nat'l Acad. Sci. (U.S.A.)* 91:5114-5118 (1994); Chatterjee *et al.*, *J. Biochem.* 114:663-669 (1993); and Shimotakahara *et al.*, *Biochemistry* 36:6915-6929 (1997), all of which are herein incorporated by reference).

Under another preferred embodiment,  $^{15}\text{N}$ ,  $^{13}\text{C}$ ,  $^2\text{H}$ -enriched recombinant proteins can be produced by acclimating a bacterial production system to grow in 95%  $^2\text{H}_2\text{O}$ . Recombinant bacterial production hosts [e.g., the BL21 (DE3) strain] can be acclimated to grow in 95%  $^2\text{H}_2\text{O}$  by successive passages in media containing increasing amounts of  $^2\text{H}_2\text{O}$ ; protein production levels of acclimated bacteria grown in 95%  $^2\text{H}_2\text{O}$  are identical to those obtained in  $\text{H}_2\text{O}$ . Using protiated [uniformly  $^{13}\text{C}$ -enriched]-glucose as the carbon source,  $^2\text{H}$ -enrichment levels of 70 - 80% can be achieved; high incorporation of  $^2\text{H}$  from the  $^2\text{H}_2\text{O}$  solvent results from metabolic shuffling during amino acid biosynthesis. While the resulting proteins are not 100% perdeuterated, they are

-17-

sufficiently enriched for the purpose of slowing  $^{13}\text{C}$  transverse relaxation rates and enhancing the sensitivity for certain types of triple-resonance NMR experiments. 100% perdeuterated samples can also be produced using  $^2\text{H}_2\text{O}$  solvent and [uniformly  $^2\text{H}$ ,  $^{13}\text{C}$ -enriched]-glucose as the carbon source.

- 5 Under one preferred embodiment, such isotope enriched proteins can be renatured by the method of Kim *et al.* which employs *in situ* refolding of proteins immobilized on a solid support. Kim *et al.*, *Prot. Eng.* 10:445-462 (1997), herein incorporated by reference. The isotope enriched proteins can also be renatured by the method of Maeda *et al.* which employs programmed reverse denaturant gradients.
- 10 Maeda *et al.*, *Protein Eng.* 9:95-100 (1996); Maeda *et al.*, *Protein Eng.* 9:461-465 (1996), both of which are herein incorporated by reference. Under another preferred embodiment, the method of Kim *et al.* is coupled with the method of Maeda *et al.* Under yet another preferred embodiment, "active" folding agents, such as the molecular chaperones GroEL/ES, dnaK, dnaJ, etc., may be used to assist in protein folding.
- 15 Nilsson *et al.*, *Ann. Rev. Microbiol.* 45:607-635 (1991), herein incorporated by reference.

- Preferably, the fusion vectors are constructed to interface with downstream refolding operations. Such vectors permit, for example, the binding of fusions to a solid support even under harshly denaturing conditions, such as high concentrations of
- 20 guanidine hydrochloride and dithiothreitol. For such purposes, the preferred class of vector employs protein-RNA fusions. Such fusion proteins can be purified using oligonucleotide affinity columns with high specificity in the presence of chaotropic agents and strongly reducing conditions.

- Under another preferred embodiment, other, non-bacterial, microbial systems,
- 25 e.g., *Pichia*-based expression systems are employed. Kocken *et al.*, *Anal. Biochem.* 239:111-112 (1996); Munshi *et al.*, *Protein Expr. Purif.* 11:104-110 (1997); Laroche *et al.*, *Bio/Technology* 12:1119-1124 (1994) Cregg *et al.*, *Bio/Technology* 11:905-910 (1993), all of which are herein incorporated by reference.

- Once the protein domain of interest has been expressed at high levels, it is
- 30 necessary to purify large quantities of the protein domain for subsequent characterization. Preferably, at least 5-10 mg of the protein domain of interests is purified. More preferably, at least 50 mg of the protein domain of interest is purified.

- Methods for preparing large quantities of a given protein of sufficient purity for domain structure modeling are generally known to those of skill in the art. Although
- 35 not all methods for protein purification are applicable to a given protein of interest, it is



generally understood that the following methods represent preferred embodiments: affinity chromatography, ammonium sulfate precipitation, dialysis, FPLC chromatography, ion exchange chromatography, ultracentrifugation, etc. For a general review of protein purification methodologies, see Burgess, *Protein Purification*, In: Oxender *et al.* (Eds.), *Protein Engineering*, pp. 71-82, Liss (1987); Jakoby, (Ed.), *Methods Enzymol.* 104:Part C (1984); Scopes, *Protein Purification: Principles and practice* (2nd ed.), Springer-Verlag (1987), and related texts, all of which are herein incorporated by reference.

#### D. Rapid Screening Of NMR And Crystallization Properties

One common problem for both NMR analysis and crystallization is poor solubility and/or slow precipitation of the protein sample. These properties are highly dependent on the pH, ionic strength, reducing agent concentration, and other properties of the buffer solvent. Thus, it is preferable to optimize these conditions to maximize solubility for NMR analysis and to optimize the conditions for protein crystallization.

Under one of the preferred embodiments of the present invention, the optimization experiments are conducted with an array of microdialysis buttons to rapidly scan a plurality of standardized buffer conditions to identify those most suitable for NMR studies and/or crystallization of each domain construct (Bagby, *J. Biomol. NMR* 10:279-282 (1997), incorporated by reference in its entirety). Preferably, each microdialysis button contains at least 1  $\mu$ L of a ~1 mM protein solution. More preferably, each microdialysis button contains at least 5  $\mu$ L of a ~1 mM protein solution. The microdialysis buttons of the present invention are commercially available. Preferably, each microdialysis button is dialyzed against about 50 ml of dialysis buffer, such as in a 50 ml conical tube (Falcon). Preferably, the dialysis is performed at 4°C. However, the dialysis can be performed at temperatures ranging from 4°-40°C. Because NMR studies are routinely performed at room temperature for extended lengths of time, it is preferable that the protein remain in solution under these conditions.

Preferably, the protein samples are initially prepared in buffers containing 50% glycerol (which is not suitable for NMR studies but generally provides good solubility) and then dialyzed against different buffers containing little or no glycerol. With respect to NMR and X-ray crystallography studies, it is understood that a person of skill in the art would know what buffers could be used to prepare the protein for study. The skilled artisan typically has a set of 50-100 standard buffers which are used to prepare protein

samples for subsequent studies. These buffers can then be modified if necessary to optimize the protein preparation. The ability of a given protein to remain soluble at high concentration or form suitable crystals is dependent on the pH of the solution, as well as the concentration of different salts, buffers, reagents, and temperature. Thus, the "button test" represents a preferred embodiment because it facilitates the rapid screening of a multitude of conditions.

This "button test" analysis typically requires 5 - 10 mg of protein sample and can be completed in a few days. Preferably, multiple samples are analyzed in parallel. Preferably, the protein samples are analyzed under a dissecting microscope to determine whether the protein has remained in solution or whether the protein has aggregated. Using the "button test" of the present invention, a single technician could score solubility properties in 100 different buffers for ~20 domains per week. Under the another preferred embodiment, these screens can be carried out using state of the art laboratory automation technology.

Alternatively, the protein domain of interest is lyophilized and then resuspended in an appropriate buffer.

Having identified the conditions under which the protein domain of interest is soluble, dynamic light scattering can be used to examine its dispersive properties and aggregation tendency in different buffer conditions. Ferré-D'Amaré *et al.*, *Structure* 15:357-359 (1994), herein incorporated by reference. Alternatively, Trp or Tyr fluorescence anisotropy can be used to measure rotational diffusion which is another measure of aggregation.

The "domain trapping" approach of the present invention includes an evaluation of NMR properties, and all of the protein samples which pass this stage of the process will already meet basic spectroscopic quality criteria. Standard criteria used to determine the basic spectroscopic quality of a given protein, which are known to those of skill in the art, include a good dispersion pattern and a narrow peak width, etc.

Preferably, gel filtration chromatography and dynamic light scattering data are collected during the course of domain purification. Such data provide information about the oligomerization state of the domain being studied.

For domains of the appropriate size (< ~30 kD), isotopically enriched samples are scored in terms of their suitability for structure determination by NMR using standard 2D HSQC, 2D NOESY, and/or 2D CBCANH triple-resonance spectra. The protein samples that provide good quality data for these NMR experiments are expected to provide good data in the full set of experiments required for automated structure

determination. For each  $^{15}\text{N}$ ,  $^{13}\text{C}$  enriched domain, this evaluation typically requires at least 5 - 10 mg of sample, and approximately 6 hours of NMR data collection.

Preferably, the evaluation is performed on about 10 mg of sample. Thus, ~20 domains can be evaluated per "spectrometer-week" using the methods of the present invention.

- 5 A "spectrometer-week", as used herein, means one skilled technician, working on one NMR machine would be able to evaluate approximately 20 domains in a given week.

Preferably, domains for structure determination by NMR are selected in an opportunistic manner, prioritizing those that provide high quality NMR data in the screens outlined above. Although some of the constructs that are generated may not be  
10 amenable to rapid structural analysis, it has been estimated that well over 50% of domains that are "trapped" by the process outlined above exhibit properties suitable for NMR or X-ray analysis. As these domains are derived from specific target genes associated with human diseases (discussed below) the chances of obtaining important new protein structures by this process are very high. Domains that provide diffraction  
15 quality crystals and which are not amenable to rapid analysis by NMR can be analyzed by X-ray crystallography.

#### **E. Computer Software And Related NMR Technologies For Fully Automated Analysis Of Protein Structures From NMR Data**

- 20 The present invention employs advanced NMR data collection and automated analysis technologies. These data collection and automated analysis technologies greatly accelerate the process of protein structure determination. Included within these technologies is a family of easy to use pulsed-field gradient triple resonance NMR experiments for rapid analysis of protein resonance assignments. See, for example,  
25 Montelione *et al.*, *Proc. Natl. Acad. Sci. (U.S.A.)* 86:1519-1523 (1989); Montelione *et al.*, *Biopolymers* 32:327-334 (1992); Montelione *et al.*, *Biochemistry* 31:236-249 (1992); Lyons *et al.*, *Biochemistry* 32:7839-7845 (1993); Rios *et al.*, *J. Biomol. NMR* 8:345-350 (1996); Tashiro *et al.*, *J. Mol. Biol.* 272:573-590 (1997); Shimotakahara *et al.*, *Biochem.* 36:6915-6929 (1997); Laity *et al.*, *Biochem.* 36:12683-12699 (1997);  
30 Feng *et al.*, *Biochem.* 37:10881-10896 (1998); and Swapana *et al.*, *J. Biomol. NMR* 9:105-111 (1997), all of which are herein incorporated by reference. These data collection and automated analysis technologies further include a fully automated strategy for determining NMR resonance assignments in proteins. Zimmerman *et al.*,

-21-

*Curr. Opin. Struct. Bio.* 5:664-673 (1995); and Zimmerman *et al.*, *J. Mol. Biol.* 269:592-610 (1997), both of which are herein incorporated by reference.

Preferably, the data collection and automated analysis technologies of the present invention employ multiple-quantum coherences in triple resonance for enhanced sensitivity. Swapna *et al.*, *J. Biomol. NMR* 9:105-111 (1997); Shang *et al.*, *J. Amer. Chem. Soc.* 119:9274-9278 (1997), both of which are herein incorporated by reference.

# **1. AUTOASSIGN: Artificial Intelligence Methods For Automated Analysis Of Protein Resonance Assignments**

10 Resonance assignments form the basis for analysis of protein structure and dynamics by NMR (Wüthrich, K., *NMR of Proteins and Nucleic Acids*, John Wiley & Sons, New York, New York (1986), herein incorporated by reference) and their determination represents a primary bottleneck in protein solution structure analysis. However, the introduction of multi-dimensional triple-resonance NMR has dramatically  
15 improved the speed and reliability of the protein assignment process. Montelione *et al.*, *J. Magn. Res.* 83:183-188 (1990); Ikura *et al.*, *Biochem. Pharmacol.* 40:153-160 (1990); Ikura *et al.*, *FEBS Letters* 266:155-158 (1990); Ikura *et al.*, *Biochem.* 29:4659-4667 (1990), Tashiro *et al.*, *J. Mol. Biol.* 272:573-590 (1997); Shimotakahara *et al.*, *Biochem.* 36:6915-6929 (1997); Laity *et al.*, *Biochem.* 36:12683-12699 (1997); Feng *et al.*,  
20 *Biochem.* 37:10881-10896 (1998), all of which are herein incorporated by reference.

Preferably, the present invention employs AUTOASSIGN, an expert system that determines protein  $^{15}\text{N}$ ,  $^{13}\text{C}$ , and  $^1\text{H}$  resonance assignments from a set of three-dimensional NMR spectra. Zimmerman *et al.*, *Proceedings of the First International Conference of Intelligent Systems for Molecular Biology* 1:447-455 (1993); Zimmerman  
25 *et al.*, *J. Biomol NMR* 4:241-256 (1994); Zimmerman *et al.*, *Curr. Opin. Struct. Bio.* 5:664-673 (1995); Zimmerman *et al.*, *J. Mol. Biol.* 269:592-610 (1997), all of which are herein incorporated by reference. AUTOASSIGN has been copyrighted by Rutgers, the State University of New Jersey. Alternatively, the present invention can employ one of the following expert systems for the automated determination of protein  $^{15}\text{N}$ ,  $^{13}\text{C}$ , and  $^1\text{H}$   
30 resonance assignments from a set of three-dimensional NMR spectra. These include a modified version of FELIX which is available from Molecular Simulation (San Diego, CA) (Friedrichs *et al.*, *J. Biomol. NMR* 4:703-726 (1994), incorporated by reference in its entirety). CONTRAST which is available from the world wide web at  
<<www.bmrb.wisc.edu/macros/soft\_contrast.html>> (Olsen and Markley, *J. Biomol.*

NMR 4:385-410 (1994), incorporated by reference in its entirety), and a series of small programs described by Meadows, *J. Biomol. NMR* 4:79-86 (1994), incorporated by reference in its entirety.

AUTOASSIGN is implemented in the Allegro Common Lisp Object System (CLOS) and requires a lisp compiler (available from Franz, Inc.) for execution. The software utilizes many of the analytical processes employed by NMR spectroscopists, including constraint-based reasoning and domain-specific knowledge-based methods. Fox *et al.*, *The Sixth Canadian Proceedings in Artificial Intelligence* 1986); Nadel *et al.*, Technical Report, DCS-TR-170, Computer Science Department, Rutgers Univ. (1986); Kumar *et al.*, *Artificial Intelligence Mag.*, Spring, 32-44 (1992), all of which are incorporated by reference in their entirety.

Input to AUTOASSIGN includes a peak-picked 2D (H-N)-HSQC spectrum and the following seven peak-picked 3D spectra: HNCO, CANH, CA(CO)NH, CBCANH, CBCA(CO)NH, H(CA)NH, and H(CA)(CO)NH. This family of triple-resonance experiments can be used together with AUTOASSIGN to automatically determine extensive sequence-specific <sup>1</sup>H, <sup>15</sup>N, and <sup>13</sup>C resonance assignments for several proteins ranging in size from 8 kD to 17 kD. Zimmerman *et al.*, *J. Mol. Biol.* 269:592-610 (1997); Tashiro *et al.*, *J. Mol. Biol.* 272:573-590 (1997); Shimotakahara *et al.*, *Biochem.* 36:6915-6929 (1997); Laity *et al.*, *Biochem.* 36:12683-12699 (1997); Feng *et al.*, *Biochem.* 37:10881-10896 (1998). The program handles some of the very challenging problems encountered in automated analysis, including missing spin systems, spin systems that overlap even in the 3D spectra, and extra spin systems due to multiple conformations of the folded protein structure (e.g. X-Pro peptide bond cis/trans isomerization). Execution times on a Sun Sparc 10 workstation range from 16 to 360 sec, depending on the complexity of the problem analyzed by the program. Preferably, the NMR spectrometer of the present invention is equipped with three channels and a fourth frequency synthesizer for carbonyl decoupling. Under another preferred embodiment, the NMR spectrometer of the present invention is equipped with four channels.

In the present invention, the AUTOASSIGN program provides for automated analysis of resonance assignments for atoms of the polypeptide backbone. Preferably, the AUTOASSIGN program of the present invention provides for fully automated analysis of resonance assignments. Having established assignments for the backbone atoms of each amino acid in the protein sequence, it is relatively straightforward to extend from these to sidechain <sup>1</sup>H and <sup>13</sup>C resonance assignments using 3D HCCH

-23-

COSY, HCCH-TOCSY, and HCC(CO)NH-TOCSY NMR experiments. Preferably, the AUTOASSIGN program of the present invention handles automated analysis of these sidechain resonance assignments. It is additionally preferred that 3D  $^{15}\text{N}$ -edited NOESY and 3D  $^{13}\text{C}$ -edited NOESY data are collected and automatically analyzed to confirm the resonance assignments.

Under one of the preferred embodiments of the present invention, AUTOASSIGN is designed to implement strategies that allow complete resonance assignments to be obtained with fewer NMR spectra. For example, sensitivity enhanced versions of HCCNH-TOCSY and HCC(CO)NH-TOCSY experiments can provide the complete set of information required for the determination of resonance assignments. This reduces the total data collection time required for determining backbone resonance assignments from the current 7 - 10 days to about half of this time. Zimmerman *et al.*, *J. Biomol. NMR* 4:241-256 (1994); Lyons *et al.*, *Biochemistry* 32:7839-7845 (1993), both of which are herein incorporated by reference.

Perdeuteration greatly lengthens the  $^{13}\text{C}$  transverse relaxation rates, allowing for higher sensitivity in these triple-resonance experiments. Grzesiek *et al.*, *J. Biomol. NMR* 3:487-493 (1993); Yamazaki *et al.*, *Eur. J. Biochem.* 219:707-712 (1994), both of which are herein incorporated by reference. It has been demonstrated that significant sensitivity-enhancement (2 - 5 fold) can be obtained with triple-resonance experiments by perdeuteration of the protein samples. Preferably, the automated assignment strategy, described herein, will utilize  $^2\text{H}$ ,  $^{13}\text{C}$ ,  $^{15}\text{N}$ -enriched proteins prepared with protiated  $^{15}\text{N}$ -H amide groups, together with deuterium-decoupled triple resonance NMR experiments. Under one embodiment, the amide NH group in the perdeuterated protein exchanges rapidly with the solvent  $\text{H}_2\text{O}$  used in the course of the protein purification to yield the protiated  $^{15}\text{N}$ -H amide groups. This strategy can provide completely automated analysis of resonance assignments for the carbon and nitrogen skeleton of the protein. Having determined these assignments, analysis of resonance assignments for the attached hydrogen atoms can be completed using HCCH-COSY, HCCH-NOESY, and HCCH-TOCSY experiments. Correction factors for  $^2\text{H}$ -isotope shift effects for each carbon site of the 20 amino acids can be determined using data from model proteins. Preferably, the complete carbon resonance assignments in their protiated forms have already been determined for these model proteins.

Preferably, the present invention utilizes high temperature superconducting probes. First generation versions of these probes are currently being marketed by Varian NMR Inst. Inc. and Bruker Inst. Such probes in combination with the above-

described technological advances reduce the time required for determining complete backbone and sidechain H, C, and N assignments to less than one week per domain.

## 2. Software For Automated Analysis Of Protein Structures From NMR Data

5 Having completed the resonance assignments for a particular protein, the next step of the structure determination process of the present invention involves analyzing secondary structure (i.e.  $\alpha$ -helices,  $\beta$ -sheets, turns, etc.). The chemical shifts themselves are often sufficient to allow identification of these features of secondary structure in the protein. Spera, *J. Amer. Chem. Soc.* 113:5490-5492 (1991); Wishart *et al.*, *J. Biomol.* 10 *NMR* 6:135-140 (1995), both of which are herein incorporated by reference. This information can be combined with other bioinformatics data derived from the protein sequence to narrow the number of possible mappings of the protein to known chain folds, and possibly even to identify the protein's biochemical function.

The principal sources of information used for the structure determination of 15 protein domains are nuclear Overhauser effect (NOE) data arising from magnetic dipole-dipole interactions between hydrogen atoms in the structure of the protein. Interpretation of these data from multidimensional NOE spectroscopy (NOESY) spectra requires the resonance assignments, which will be obtained (as described above) in an automated manner. Preferably, the present invention employs software for automated 20 analysis of NOESY spectra and the generation of input files for rapid structure calculations using stimulated annealing of experimental constraint functions with molecular dynamics calculations.

The problems encountered in automatically analyzing NOESY spectra are due largely to spectral overlaps, i.e., it is often the case that several hydrogen atoms have 25 very similar resonance frequencies. One of the preferred approaches to resolving this problem is to use 3D (or 4D)  $^{15}\text{N}$ - or  $^{13}\text{C}$ -resolved NOESY experiments (Clare *et al.*, *Ann. Rev. Biophys. Biophys. Chem.* 20:29-63 (1991); Clare *et al.*, *Prog. Biophys. Mol. Bio.* 62:153-184 (1994); Clare *et al.*, *Methods Enzymol.* 239:349-363 (1994), all of which are herein incorporated by reference), in which one (or both) of the two protons 30 involved in the NOE interaction is resolved in a third (or fourth) frequency dimension based on the frequency of the  $^{15}\text{N}$  or  $^{13}\text{C}$  nucleus to which it is covalently bound. Symmetry features of the 3D  $^{13}\text{C}$ -edited spectra can also be used to great advantage.

Another preferred approach to resolving ambiguities that arise in assigning NOESY cross peaks to specific pairs of interacting hydrogen atoms is to use the

-25-

secondary structure (i.e.  $\alpha$  helix,  $\beta$  strand, etc.) to predict NOEs that are expected and to use these structural predictions to guide the analysis of NOESY spectra. Meadows *et al.*, *J. Biomol. NMR* 4:79-96 (1994), herein incorporated by reference.

- 5 A third preferred approach is to use a low-resolution structure of the protein obtained in a first pass analysis of the uniquely assigned NOESY cross peaks to identify candidate assignments of the remaining unassigned NOESY cross peaks which are inconsistent with the low-resolution structure.

- The approaches outlined above are those that are routinely used by a human expert in the analysis of NOESY spectra. Under the preferred embodiment, the reasoning processes of those approaches are encoded into the software of the present invention. Preferably, the software program of the present invention is a C++ program. AUTO\_STRUCTURE is a C++ program that analyzes 2D and 3D NOESY spectra to identify unique NOESY crosspeak assignments (Gaetano Montelione, Y. Huang and Robert Tejero (Rutgers, The State University of New Jersey)). The program then uses these crosspeak assignments to create distance-constraint input files for simulated annealing structure calculations. AUTO\_STRUCTURE can also use a low-resolution (or homology-modeled) structure of the protein to filter the list of NOESY crosspeaks that are not uniquely assigned, removing potential NOE assignments that are severely inconsistent with the low-resolution structure. AUTO\_STRUCTURE propagates the structural constraints imposed by the uniquely assigned NOEs to determine assignments of otherwise ambiguous NOEs. AUTO\_STRUCTURE can successfully analyze NOESY spectra and, in an iterative fashion, automatically generate 3D structures of simple polypeptides. Other auto structure programs for NOESY analysis that can be used in the present invention include GARANT (Wuthrich (ETH, Zurich, Germany), incorporated by reference in its entirety), ARIA (Michael Nilges, *J. Mol. Biol.* 245:645-660 (1995), incorporated by reference in its entirety) and NOAH (Mumenthaler and Braun, *J. Mol. Bio.* 254:465-420 (1995), incorporated by reference in its entirety).

- Preferably, the auto structure program of the present invention provides for automated analysis of protein or protein domain structures. Under a more preferred embodiment, the auto structure program of the present invention further contains sophisticated reasoning processes which can assist in resolving ambiguous NOESY crosspeak assignments in the absence of even a low resolution 3D structure. Preferably, this includes (i) the propagation of structural constraint information inherent in the secondary structure analysis stemming from the resonance assignments and (ii) the application of pattern recognition algorithms.



**F. Mapping New Domain Structures To Proteins In The Protein Data Base (PDB) With Similar Structures And Biochemical Functions**

Preferably, the resulting domain structures derived from NMR or X-ray  
5 crystallographic analyses are compared with the PDB or other suitable databases of  
known protein structures using an algorithm for 3D-structure homology matching.  
Examples of publicly available PDBs suitable for use in the present invention include  
the Protein Data Base (PDB), which can be found at <http://www.pdb.bnl.gov/>.  
Algorithms for 3D-structure homology matching suitable for use in the present  
10 invention include the DALI analysis program (Holm *et al.*, *J. Mol. Biol.* 233:123-138  
(1993), herein incorporated by reference), the CATH analysis program (Orengo, C. A.,  
*Structure* 5:1093-1108 (1997), herein incorporated by reference), VAST  
(<http://www.ncbi.nlm.nih.gov/Structure/vast.html>; Gibrat *et al.*, *Current Opinion in*  
*Structural Biology* 6: 377-385 (1996); and Madej *et al.*, *Proteins* 23: 356-369 (1995), all  
15 of which are incorporated by reference in their entirety) or similar algorithms for 3D-  
structure homology matching.

DALI compares "contact maps" of protein structures to identify homologies in  
3D structure and provides a list of PDB entries with high match scores. Based on  
current "hit" rates by newly-determined structures against already known folds (Holm *et*  
20 *al.*, *Methods Enzymol.* 266:653-662 (1996); Holm *et al.*, *Science* 273:595-603 (1996),  
both of which are herein incorporated by reference), it is expected that greater than 50% of  
the structures will show significant structural and functional homology to proteins of  
known structure and function.

In order to facilitate and enhance the ability to identify common biochemical  
25 functions for these DALI hits, it is preferable to develop a structure-function knowledge  
base (Figure 1), correlating each protein structure in the PDB with the set of  
biochemical functions that have been associated with that protein in the published  
scientific literature. Where information is available, this knowledge base will also  
correlate the portions of these known protein structures with corresponding specific  
30 biochemical functions (e.g., enzymatic active sites or nucleic-acid binding loops). This  
fold-function knowledge base is applicable to a wide range of structural bioinformatics  
applications, and of significant utility to the nascent industry of structural  
bioinformatics.

Once novel protein domains with clear homologies to better-characterized  
35 counterparts have been identified, the proposed functions can be validated using

-27-

biochemical assays. For example, if a protein looks like a member of the galactosyl transferase family, the protein will be tested for radioactive UDP-galactose (or other carbohydrate) binding, if it looks like a lipase, the protein will be tested for lipid binding and/or hydrolysis activity, and so on.

5                    **G.    Integration Into A Large-Scale, High-Throughput  
                     "Engine" For Structural And Functional Analysis Of  
                     Hundreds Of Human Genes**

                     Under one preferred embodiment, the present invention provides for a "structure  
- function analysis engine" capable of high-throughput discovery of biochemical  
10    functions of new human disease genes and genes of unknown function.

                     Using conventional methodology, the skilled artisan may be able to determine  
the 3D structure of one protein per year. However, using the methodology of the  
present invention, it is possible to determine the 3D structure of far greater than one  
protein per year. Under optimal conditions, the present invention will enable a properly  
15    equipped laboratory to generate the 3D structure of one protein per month per NMR  
machine. As used herein, "high-throughput" refers to the ability to determine the 3D  
structures of protein domains of unknown function at a rate which is faster than the rate  
at which a skilled artisan could determine a protein structure using traditional  
methodologies.

20                    One of the central features of the present invention is that it is highly scaleable.  
Under one of the preferred embodiments, the high-throughput "engine" consists of a  
dedicated laboratory staffed with artisans skilled in relevant arts (e.g., NMR and X-Ray  
crystallography, molecular biology, biochemistry, etc.). Preferably, such a laboratory is  
further equipped with state of the art equipment for the sequencing, sub-cloning,  
25    expression, purification, screening and analysis of the protein domains of interest. The  
rate limiting component of this high-throughput "engine" is the number of NMR  
machines within the laboratory. Thus, the rate at which protein domains can be  
characterized will increase with the addition of additional NMR machines. Unlike  
conventional methodology, the present invention provides a method for determining the  
30    3D structure of unknown protein domains whose rate is not solely dependent on the  
number of artisans skilled in 3D protein structure determination.

                     The rate of domain characterization increases as each of the tasks which are  
presently conducted by hand are automated. For example, under one of the preferred  
embodiments, the parsing of the unknown gene into its component domains is

facilitated through the use of advanced sequence analysis algorithms. Under another of the preferred embodiments, the rate of domain characterization is increased through the use of improved computer software for the automated analysis of NMR datapoints.

Although the present invention is drawn to using NMR to determine protein structure and function, it is to be understood that a person of skill in the art could perform similar analysis using X-ray crystallography to practice the present invention. Shapiro and Lima, *J. Structure* 6:265-267 (1998); Gaasterland, *Nature Biotech.* 16:625-627 (1998); Terwilliger *et al. Prot. Sci.* 7:1851-1856 (1998); Kim, *Nature Structure Biology (Synchrotron Supp.)*: 643-645 (1998), all of which are incorporated by reference in their entirety.

### III. SPECIFIC GENE TARGETS

Preferably, the specific gene targets that will be analyzed using the present invention will be genes that are known to be involved in human diseases but for which the biochemical function and three-dimensional structures of the proteins encoded by the genes are not available. These protein domains will be analyzed using the high-throughput "structure - function analysis engine" of the present invention. The resulting structural and functional information will be critical in developing pharmaceuticals targeted to these human gene products.

Although the present invention is principally drawn to human genomic, cDNA and mRNA sequences, it is to be understood that the present invention is generically applicable to genomic, cDNA and mRNA sequences of any living organism or virus.

Although the present invention is capable of determining the function of any given protein or protein domain, the preferred biomedical gene targets of the present invention include Alzheimer's  $\beta$  peptide precursor protein (APP). Additional preferred biomedical gene targets include but are not limited to those genes implicated in neoplastic, neurodegenerative, metabolic, cardiovascular, psychiatric and inflammatory disorders. The genomes/genes of infectious agents, such as pathogenic microbes, pathogenic fungi and pathogenic viruses, are also preferred targets for study.

By focusing on medically important diseases, it is anticipated that the present invention will greatly facilitate the identification of protein targets for subsequent drug discovery efforts.

-29-

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration and are not intended to be limiting on the present invention.

**EXAMPLE 1**

5

**PARSING OF THE APP GENE INTO  
DOMAIN-ENCODING REGIONS**

**A. Parsing By The Exon Phase Rule**

The human amyloid beta peptide precursor (APP) protein gene (Yoshikai *et al.*, *Gene* 87:257-263(1990)) was subjected to a parsing analysis with respect to the phases

10 of its exon-exon boundaries:

	<u>Exon-exon boundary</u>	<u>Phase</u>
	1 - 2	0
	2 - 3	0
	3 - 4	1
15	4 - 5	0
	5 - 6	2
	6 - 7	1
	7 - 8	1
	8 - 9	1
20	9 - 10	0
	10 - 11	0
	11 - 12	0
	12 - 13	0
	13 - 14	1
25	14 - 15	1
	15 - 16	1
	16 - 17	0
	17 - 18	0

30 Using the exon phase rule, only exons or exon combinations that start or stop in the same phase are allowed. For example, exon 7 or exons 7+8 are potential domain encoding regions with phase 1 boundaries. Likewise, exon 10, exons 10+11, and exons 10+11+12 would be potential domain encoding regions with phase 0 boundaries.

**B. Exon Phase And The Alternative Splicing Rule**

The APP gene is reported to be alternatively spliced. The longest polypeptide encoded by the APP gene is 770 amino acids long, and shorter isoforms exist that are missing the amino acids encoded by exons 7, 8, and/or 15 (Sandbrink *et al.*, *Ann. NY Acad. Sci.* 777:281-287 (1996), herein incorporated by reference). All of these exons which are alternatively spliced are bounded by phase 1 termini. Alternative splicing must be done in such a way as to not disrupt the integrity of the holoprotein (i.e., without destroying essential folding information). The fact that all alternatively spliced exons have phase 1 termini implies that domain boundaries may be congruent with phase 1 exon boundaries, that is, phase 1 exon boundaries in this particular gene are candidate boundaries of domain encoding regions.

**C. Setting The Phase With Known Internal Domain Structures**

Exon 7 of APP is known to encode a complete domain for a Kunitz-type serine protease inhibitor (Hynes *et al.*, *Biochemistry* 29:10018-10022 (1990)). The Kunitz inhibitor is a domain that has been combinatorially shuffled around in various genes during evolution (Patty, L. *Curr. Opin. Struct. Biol.* 1:351-361 (1991)), and for the reasons given above it would have to be inserted only into proteins with other domains of the same phase in order to not disrupt gene expression. Therefore, this analysis is also consistent with APP being composed of domains which are bounded by phase 1 exon termini.

**D. The "N-Terminus First" Strategy Of Parsing**

In order to reduce the combinatorial complexity of the parsing problems, an "N-terminus first" strategy is preferred. In this parsing strategy, expression constructs of putative domains are made starting from the N-terminus of the protein and extending to the likely C-termini as predicted by the above rules. These constructs are put through the "domain trapping" test of the present invention in order to identify the first N-terminal domain. Then, once the first N-terminal domain is identified, a second set of constructs commencing from the C-terminus of the first N-terminal domain is made, and so on.

In the case of APP, the N-terminus of the protein starts with exon 2 because exon 1 encodes a signal peptide. Therefore, the possible domain constructs that ended in phase 1 boundaries were exons 2-3 and exons 2-6 (exon 7 was known to encode the Kunitz inhibitor domain). By the domain trapping criteria exons 2-3 were found to

-31-

encode the first N-terminal domain, so a second construct composed of exons 4-6 was made and found to contain the second domain of APP, and so on. A summary of the APP domains identified by this combination of parsing and domain trapping is given below:

5	<u>Domain</u>	<u>Encoding Exons</u>
	1 (N-terminal domain)	2-3
	2	4-6
	3 (Kunitz inhibitor)	7
	4	8
10	etc.	

### EXAMPLE 2

#### EXPRESSION AND PURIFICATION OF AN ISOLATED DOMAIN

The putative domain regions identified in Example 1 are sub-cloned into the secretion-based protein A fusion expression system and purified. Nilsson *et al.*,  
 15 *Methods Enzymol.* 185:144-161 (1990), herein incorporated by reference.

### EXAMPLE 3

#### EXPRESSION AND PURIFICATION OF AN ISOLATED DOMAIN FOR NMR ANALYSIS

##### A. Protein Expression

20 *E. coli* strain RV308 is used as the bacterial expression host. Competent RV308 cells are transformed with pHAZY plasmid containing the NTD 2-3, Z domain insert. Cells are grown overnight at 37°C on LB agar plates supplemented with 100 g/ml ampicillin (Sigma). Fresh transformants are used to inoculate seed cultures in 2 x TY media (16 g/l typtone, 10 g/l yeast extract, and 5/g NaCl) supplemented with 100  
 25 µg/ml ampicillin. Cultures are grown overnight at 30°C in 250 ml baffled flasks. A ratio of 1 to 25 is used to inoculate expression cultures. For 1 liter of MJ media expression culture (2.5 g/l <sup>15</sup>NH<sub>4</sub> sulfate (>98% purity), 0.5 g/l sodium citrate, 100 mM potassium phosphate buffer, pH 6.6, supplemented with 5 g/l <sup>13</sup>C-glucose (>98%  
 30 purity), 1 g/l magnesium sulfate, 70mg/l thiamine, 1 ml of 1000 x trace elements solution, 1 ml of 1000 x vitamin solution, and 100 mg/l ampicillin), 40 ml of seed culture is spun down by centrifugation. Bacterial pellets are washed, resuspended in fresh MJ media, and used to inoculate expression cultures. Cultures are grown at 30° in

-32-

2 l baffled flasks and induced at OD<sup>55</sup> 0.9 – 1.0 with indole acrylic acid to a final concentration of 20 mg/l. Cultures are harvested 15 hours after induction by centrifugation. Bacterial pellets are stored at 20°C until purification.

#### B. Protein Purification

- 5 Bacterial cells are resuspended in 100 ml of 25 mM Tris, pH 8.0, 5 mM EDTA, 0.5% Triton X-100 and sonicated continuously for 9 minutes. Released inclusion bodies are pelleted by centrifugation and washed with fresh sonication buffer. Inclusion bodies were then solubilized with 7 M guanidine HCl and 10 mM DTT. Centrifugation is used to pellet any undissolved material. Guanidine and DTT are then diluted twenty  
10 fold by dialysis against twenty volumes of 10 mM HCl.

- IgG affinity purification is used to purify the NTD 2-3. Z domain fusion from any contaminating proteins. The 10 mM HCl protein solution is neutralized to > pH 7 with 1 M Tris, pH 8.0. The sample is then applied to an IgG sepharose column (Pharmacia) pre-equilibrated with TST buffer. The column is washed with 10 bed  
15 volumes of TST (50 mM Tris, 150 mM NaCl, and 0.05% TWEEN™ 20) followed by 2 bed volumes of 5 mM ammonium acetate, pH 5.0. Finally, the protein is eluted with 0.5 M acetic acid, pH 3.4. In preparation for refolding, the protein eluate is neutralized to pH 8.0 with solid Tris, and an equal volume of 7 M guanidine is added to bring the final guanidine concentration to 3.5 M.

- 20 Refolding of the protein is carried out by using dialysis to slowly dilute out the guanidine HCl while slowly introducing the refolding buffer. Firstly, Spectra/POR dialysis tubing with a MWCO of 6000-8000 is soaked overnight in water in order to remove glycerol. Next, the protein solution is loaded into the primed tubing and dialyzed against fresh refolding buffer. The dialysis reaction is incubated for two days  
25 at 4°C with magnetic stirring. Refolded protein is then concentrated using an IgG sepharose column pre-equilibrated with TST buffer. Bound protein is eluted with 0.5 M acetic acid and collected in fractions in order to keep the volume as low as possible. Refolded fusion protein is then further purified by gel filtration on a Pharmacia Superdex 75 FPLC column using 300 mM ammonium bicarbonate, 0.1 mM copper  
30 sulfate as the buffer. Fractions corresponding to the fusion protein are pooled, and the protein is quantitated using the optical density at 280 nm.

Cleavage of the fusion protein is carried out using Genenase I (NEB), a variant of subtilisin BPN'. Fusion protein is buffer exchanged into Genenase buffer, 20 mM Tris, pH 8.0, 200 mM NaCl, 0.02% NaN<sub>3</sub>, using an Amicon stir cell. The protein

-33-

concentration is adjusted to 2 mg/ml and Genenase is added to a concentration of 0.2 mg/ml. The reaction is incubated at room temperature for 4 days and the extent of cleavage was followed using SDS-PAGE. Cleaved NTD 2-3 is separated from uncleaved fusion and Z domain by passing the solution over an IgG column and collecting the unbound NTD 2-3 in the flow through. The NTD is then purified from Genenase by gel filtration on a Pharmacia Superdex 75 FPLC column using 300 mM ammonium bicarbonate, 0.1 mM copper sulfate as the buffer.

#### EXAMPLE 4

##### DOMAIN TRAPPING: CHARACTERIZATION OF AN ISOLATED DOMAIN

Characterization of an isolated domain (NTD2-3) from the Alzheimer's amyloid precursor protein (APP) by circular dichroism measurements in the far UV shows an ellipticity minimum at 222 nm, indicative of  $\alpha$ -helical secondary structure (Figure 2A). Of even greater significance, CD measurements at longer wavelengths reveal a clear signal in the aromatic region around 280 nm, consistent with the presence of Trp, Tyr, and Phe chromophores in an ordered environment such as would be expected in the hydrophobic core of a folded protein (Figure 2B). A moderately concentrated solution (~100  $\mu$ M) of the isolated N-terminal domain is further characterized by one-dimensional  $^1$ H-NMR. The isolated recombinant APP N-terminal domain exhibits high dispersion of the proton resonances, which is a signature of well-folded polypeptides (Figure 3).

A time-course of amide hydrogen-deuterium exchange measurements is performed. From this, it is observed that many backbone NH groups exhibit significant protection, indicating hydrogen-bonded secondary structure stabilized by tertiary interactions consistent with a well-folded domain structure (Figure 4). Finally, thermal denaturation experiments, monitored by intrinsic tryptophan fluorescence, are performed. These experiments show that the recombinant APP NTD2-3 domain undergoes a cooperative thermal unfolding transition, with a  $T_m$  of approximately 60° C, indicative of a compact domain structure (Figure 5).

Thus, using biophysical data alone, it is demonstrated that the NTD2-3 domain of APP, encoded by exons 2 and 3, is expressed as a well ordered tertiary structure. Chiang *et al.*, *Neurobiol. Aging*, Supplement Vol. 17, No. 4S, abstract 393 (1996).



Similar studies indicate that the next APP N-terminal domain is encoded by exons 4-6, the third (Kunitz) domain by exon 7, and so on.

### EXAMPLE 5

#### NMR CHARACTERIZATION OF THE NTD 2-3 DOMAIN

5 For NMR studies NTD 2-3 is concentrated to concentrations greater than 10 mg/ml. Gel filtration pure NTD 2-3 is first buffer exchanged into a NMR compatible buffer, 20 mM potassium phosphate, pH 6.5 using an Amicon stir cell. The protein solution is then concentrated to an appropriate volume based on the amount of protein present using the Amicon 50 and Amicon 3 stir cells. The final protein concentration is  
10 confirmed by optical density at 280 nm.

NMR  $^{15}\text{N}$ -HSQC spectra is collected on a Varian Unity 500 spectrometer. The  $^{15}\text{N}$ -HSQC spectral analysis is shown in Figure 6. The good dispersion in both the  $^{15}\text{N}$  and  $^1\text{H}$  dimensions demonstrate that this is a folded domain that has been "trapped" by the presently described methods.

15

### EXAMPLE 6

#### COMPARISON OF THE NMR STRUCTURE OF CSPA WITH OTHER PROTEINS

Recombinant CspA is expressed and purified using the protocol essentially as described by Chatterjee *et al.*, *J. Biochem.* 114:663-669 (1993), and Feng *et al.*,  
20 *Biochemistry* 37:10881-10896 (1998), both of which are incorporated by reference in their entirety. The purified CspA protein is prepared for NMR analysis by dialysis against a buffer containing 50 mM potassium phosphate and 1 mM  $\text{NaN}_3$ , pH 6.0 and the sample is analyzed using a Varian Unity 500 spectrometer equipped with three channels and a fourth frequency synthesizer for carbonyl decoupling as described by  
25 Feng *et al.*, *Biochemistry* 37:10881-10896 (1998). Figure 7 provides the 2D  $^{15}\text{N}$ - $^1\text{H}$  HSQC spectrum of CSPa at pH 6.0 and 30°C.

The collected spin resonances are analyzed using AUTOASSIGN. The input for AUTOASSIGN includes peaks from 2D  $^{15}\text{N}$ - $^1\text{H}$  HSQC and 3D HNCO spectra along with peak lists from three intraresidue (CANH, CBCANH and HCANH) and three  
30 interresidue (CA(CO)NH, CBCA(CO)NH and HCA(CO)NH) experiments, which correlate with the  $\text{C}^\alpha$ ,  $\text{C}^\beta$  and  $\text{H}^\alpha$  resonances of residues  $i$  and  $i-1$  respectively. The

results of the AUTOASSIGN analysis of the peak picked 2D and 3D NMR spectra are summarized in Table 1.

Side chain resonance assignments are obtained using PFG HCCNH-TOCSY and PFG HCC(CO)NH-TOCSY and homonuclear TOCSY experiments recorded with multiple mixing times of 22, 36, 45, 54, 71 and 90 ms according to the method of Celda and Montelione. *J. Magn. Reson. B101*:189-193 (1993), incorporated by reference in its entirety. Interatomic distance constraints are derived from three NOESY data sets 2D NOESY and 3D  $^{15}\text{N}$ -edited NOESY-HSQC spectra recorded with a mixing time of  $t_m$  of 60 ms of a CspA sample dissolved in 90%  $\text{H}_2\text{O}$ /10%  $^2\text{H}_2\text{O}$  and a 2D NOESY spectrum is recorded with a mixing time  $t_m$  of 50 ms of a sample dissolved in 100%  $^2\text{H}_2\text{O}$ . The intensity of the NOESY-HSQC spectrum is corrected for  $^{15}\text{N}$  relaxation effects, and the cross-peak intensities are converted into interproton distance constraints.

Table 1					
Summary of AUTOASSIGN Analysis for CspA Triple-Resonance NMR Data					
Residues	69		Number of assignments (expected)	AUTOASSIGN analysis	Manual analysis
			Backbone		
GSs expected	66		$\text{H}^{\text{a}}$	65	66
GSs observed	67		$\text{H}^{\text{a}}$	77	79
Degenerate GS roots	8		$^{15}\text{N}$	65	66
Assigned GSs	65		$^{13}\text{C}^{\text{a}}$	67	69
Extra GSs	2		$^{13}\text{C}^{\text{a}}$	64	66
Assigned residues	68		$^{13}\text{C}^{\text{b}}$	49	59
Percent assigned residues	99%		Side chain		
Execution times (sec.)	10		$^{15}\text{N}$	6	6
			$\text{H}^{\text{a}}$	11	11

Stereospecific assignments of methylene  $\text{H}^{\text{b}}$ s are made by analysis of local NOE and vicinal coupling constant data using the HYPER program. HYPER is a conformational grid search program used for determining stereospecific  $\text{C}^{\text{b}}\text{H}_2$  methylene proton assignments and for defining the ranges of dihedral angles  $\phi$ ,  $\psi$ ,  $\chi^1$  that are consistent with the local experimental NMR data for each amino acid in a polypeptide (Tejero *et al.*, *J. Biomol. NMR* (in press), incorporated by reference in its entirety). The secondary structural elements of CspA are summarized in Figure 8. From this information, five  $\beta$ -strands corresponding to polypeptide segments of residue 5-13, 18-22, 30-33, 50-56 and 63-70 are identified.

The average number of distance constraints per residue is 10.4. Dihedral angle constraints are obtained from the HYPER program. Structure generation calculations are carried out with DIANA, version 2.8 (TRIPOS, Inc.) using R8000 processor in a Silicon Graphics Onyx workstation (Braun and Go, *J. Mol. Biol.* 186:611-626 (1985), and Guntert *et al.*, *J. Mol. Biol.* 169:949-961 (1983), both of which are incorporated by reference in their entirety).

From this NMR data set, the solution structure of CspA is reasonably well defined. Using the refined CspA coordinates defined by the present invention, structural database searches of the Protein Data Base (PDB) are performed with the DALI program. This search is able to identify a list of proteins or domains of structural homologues. Identified structural homologues of CspA exhibiting similar biochemical function include the RNA binding domain of *E. coli* polyribonucleotide nucleotidyltransferase, the human mitochondrial ssDNA-binding protein, *E. coli* translation initiation factor I, the ssDNA-binding protein from gene V of filamentous bacteriophages M13 and f1, the ssDNA-binding protein from *Pseudomonas* phage Pf3, elongation factor G from *Thermus thermophilus*, a domain of *E. coli* lysyl tRNA synthetase, a domain of yeast tRNA synthetase, human replication protein A, staphylococcus nuclease, and a domain of *E. coli* topoisomerase I. Although the function of CspA was already known, the present Example has illustrated the use of the present invention.

As the present invention describes, a person of skill in the art is able to take a polypeptide of unknown function, express and purify a stable peptide domain encoded by the polypeptide, determine the NMR 3D structure of that expressed domain and predict the function of that domain by comparing the structure of that domain against known structures having known functions. This represents a fundamental paradigm shift in the study of proteins.

#### EXAMPLE 7

#### **AUTOMATED ANALYSIS OF PROTEIN STRUCTURES FROM NMR DATA**

Figure 9 outlines the constraint reasoning system of the present invention which automatically generates protein structures from NMR data. Briefly, the constraint reasoning system is based on automated analysis of secondary structure, prediction of hydrophobic core contacts, and iterative analysis of contact frequencies. The constraint

-37-

reasoning generates reliable initial chain folds even when the chemical shift information alone provides few unambiguous NOESY cross peak assignments.

In the first step, a Simple Match is performed to determine all possible assignments (A-type matches) for each spectra. In the second step, the expected peaks which are consistent with secondary structure, or which are intra/seq are identified. These peaks are placed in an experimental (E) and an unknown (U) set. The expected peaks are further used to create a dynamically locally referenced values (DLRV) for H and HX (local referencing). The DRLV for each atom in each dimension includes the original chemical shift value plus any additional chemical shift values derived from the E set. If only one expected match is found for a given peak, that peak is put into U and E set. If more than one expected match is found for a given peak (B-type expected matches), those expected matches are also put into U and E set.

In the third step, the local match tolerance for HX dimension is defined. The local match tolerance for HX dimension is based on assigned HX resonance from E set. HX resonance is performed as described by Koide *et al.*, *J. Biomol. NMR* 6:306-312 (1995); Bai *et al.*, *Proteins* 20:4-14 (1994); and Englander and Mander, *Annu. Rev. Biophys. Biomol. Struct.* 21:243-265 (1992), all of which are incorporated by reference in their entirety.

In the fourth step, U peaks are supplemented based on chemical shift (unambiguous) data filtered through a noise filter. The noise filter reduces the background noise by eliminating peaks having an intensity of <0.05% of the highest intensity of the real intra peaks. Thus, a tighter match tolerance to chemical shift list is created by the noise filter makes than the list created by the Simple Match of step 1.

B-type matches, a subset of A-type matches for each spectra, are defined in step 5. The B-type matches for a given peak are defined by ordering the A-type matches based on the size of the match value. The match value is computed as follows:

$$MV = \min(\Delta HX + \Delta X/10 + \Delta H)$$

where  $\Delta H = H_{\text{obs}} - H_{\text{DCSL}}$ ;  $\Delta HX = HX_{\text{obs}} - HX_{\text{DCSL}}$ ;  $\Delta X = X_{\text{obs}} - X_{\text{DCSL}}$ ; and  $H_{\text{DCSL}}$ ,  $HX_{\text{DCSL}}$  and  $X_{\text{DCSL}}$  are sets of dynamically locally referenced values (DLRV) for the H, HX, and X dimensions, respectively. All possible matches with  $\gamma \leq 0.01$  are chosen, where  $\gamma = |MV - (\Delta HX + \Delta X/10 + \Delta H)|$ .

In step 6, the Contact Frequency (CF) of E is used to assign B-type matches to U set. A contact bin is created from all E's. If a peak in B is in the contact bin, it is

-38-

assigned to U. Otherwise, it is assigned to T-type matches. In step 7, SYM, a constraint satisfaction program, is used to assign B-type matches to U set. If a peak in B has symmetry to another peak in B, both are assigned to U set as T-type assignments. SYM modeling is performed utilizing the method described by Gdaniec *et al.*,

- 5 *Biochemistry* 37:1505-1512 (1998); Easterwood and Harvey, *RNA* 3:577-585 (1997); Laing and Hall, *Biochemistry* 35:13586-13596 (1996); Ericson *et al.*, *J. Mol. Biol.* 250:407-419 (1995); and Foucrault and Major, *ISMB* 3:121-126 (1995), all of which are incorporated by reference in their entirety. In step 8, HP-CORE, which predicts buried residues, is used to assign B-type matches to U set. A HP-CORE contact bin is created  
10 from all B's. If the contract frequency (CF) of the HP-CORE contact bin is  $> N$ , all peaks in this bin are assigned to U as T-type assignments.  $N$  is a heuristic value that is scale with the number of NOESY spectra available.

- The 3D structure of the protein is computed in step 9. First, the structure calculation program is calibrated, where the distance of D-type peaks are derived from  
15 their intensity and the distance of T-type peaks are  $= 5.0 \text{ \AA}$ . The structure calculation program is then run. The 10 best results, from a family of 50 3D structures are selected. For each of the 10 best results, the  $S(\phi)$ ,  $S(\varphi)$ ,  $\sigma(i,j)$  matrix, bb root mean square deviation (RMSD) are calculated where records with a  $S(\phi) < 0.7$  and  $S(\varphi) < 0.7$  are excluded. If the rmsd is too large, further analysis is stopped. If the rmsd is  $< 1 \text{ \AA}$ , the  
20 analysis continues with step 12. If it has progress, analysis continues with step 10. If there isn't any more progress, analysis proceeds with the next cycle (decrease O). Disordered regions - order (i,j) are identified from O. If  $(\langle S - O \rangle \geq 0$  and  $(\sigma(i,j) - 2/O) \leq 0)$  and  $\text{order}(i,j) = 1$ , then the region is ordered. If  $\text{order}(i,j) = 0$ , then the region is disordered.

- 25 In the validation step, step 10, peaks that consistently violated NOE assignments are removed from U list. If the peak is greater than the Violation Parameter (V), it is assumed that the assignment is wrong. If  $\text{order}(i,j) = 1$ , then  $V = 1$  and if  $\text{order}(i,j) = 0$ , then  $V = 2$ . If the  $v_{\text{min}}(i,j)$  is greater than V and it is a T-type assignment, it is deleted from the assignment list. If it is a D-type assignment, it is downgraded to a T-type  
30 assignment and assigned an alternate assignment of  $\langle d \rangle < 5 \text{ \AA}$ . If a peak has more than one T-type assignment and only one of the peaks has violated V, it is reassigned as a D-type assignment.

- In step 11, expected peaks that are consistent with 3D structure are identified and placed in U set. It is assumed that if the peak is in an ordered region and it is  
35 greater than the Distance Cutoff (D), it is an incorrect assignment. If  $(\text{order}(i,j) = 1)$ ,

-39-

then  $D = 5 + \text{rmsd} \times 2$  and  $D_{\min} = 5.5 \text{ \AA}$ . N, the number of possible assignments left, is put into U set. If  $\text{rmsd} > 2$ , then  $N \leq 2$ . If  $\text{rmsd} > 1$ , then  $N \leq 3$ . For any other rmsd value,  $N \leq 4$ . Any assignment with a  $d_{\text{mm}}(i,j) > D$  in ordered region is removed from A list. If N possible assignments are left, they are put into U set as T-type assignments.

- 5 In set 12, all possible NOE's that are expected from the structure are back calculated. Any predicted assignments not in U or A list and any peak still in A list are outputted. For each cycle, a Contact Map (assignment, structure), Connectivity Map, Structures, Assignments (ordered by intra, seq, mid, long range),  $S(\phi)$ ,  $S(\psi)$ ,  $\sigma(i,j)$  matrix, and bb rmsd are outputted.

10

### EXAMPLE 8

#### AUTOMATED GENERATION OF 3D STRUCTURES

The constraint reasoning system, outlined in Figure 9 and described in Example 7, is used to automatically generate the 3D structures of the Zdom and Cspa proteins (Figures 10A and B, and Figure 17, respectively). The constraint reasoning system  
15 generated 3D structures are compared to the manually generated 3D structures. The results of the automated assignment analysis for Zdom and Cspa are presented in Figures 11-13 and 18-20, respectively. The results of the manual assignment analysis for Zdom and Cspa are presented in Figures 14-16 and 21-23, respectively. Backbone – backbone assignments are designated by x. Backbone – side chain assignments are  
20 designated by o. Side chain – side chain assignments are designated by □. Intra-residue assignments are designated by filled symbols.

- In a further embodiment, a constraint reasoning system for automatically generating protein structures from NMR data is employed. A variety of constraints have been used to resolve the ambiguity problem in analysis of 2D and 3D NOESY  
25 spectra, obtain an initial chain fold, and then use constraints implied by this initial structure to iteratively refine the protein structure. The constraint reasoning system is based on automated analysis of secondary structure, prediction of hydrophobic core contacts, and iterative analysis of contact frequencies. The constraint reasoning system can generate reliable initial chain folds even when the chemical shift information alone  
30 provides few unambiguous NOESY cross peak assignments. Experimental NMR data for two different proteins have been analyzed to automatically generate 3D structures. The structures generated by this constraint reasoning system in hours are in good

agreement with those derived from manual analysis processes which require weeks or months.

The NOESY-Assign constraint reasoning system for this purpose comprises the following 12 steps:

- 5           Step 1: Simple Match – get all possible assignments (A-type matches) for each spectra.
- Step 2: Identify expected peaks which are intra/seq. or consistent with secondary structure. Put in U and E set. Create dynamically referenced values (DLRV) for H and HX (local referencing).
  - 10           The DLRV for each atom in each dimension includes the original chemical shift value plus any additional chemical shift values derived from E set.
  - Given a peak, if only one expected match is found, put in U and E set. If found more than one expected match is found, select B-type
  - 15           expected matches, put in U and E set. See Step 5 for explanation of B-type match.
  - \* Not for 2D spectra
  - All assignments are D-type assignments
  - Remove all that are inconsistent with secondary structure
  - 20           \*\*\* Possible features \*\*\*
  1. Check if the data set are consistent with each other
    - List the residue that no intra HN – Ha in N15-NOESY
    - List the residue that no intra Ha – Hb in C13-NOESY
  - If have, let the user do local re-refercing or global re-referencing
  - 25           2. Do referencing refinement
- Step 3: Define local match tolerance for HX dimension based on assigned HX resonance from E set.
  - \* Not for 2D spectra
  - Define local match tolerance for HX dimension:
    - 30           For each possible HX dimension assignment, find all assignments in E set, calculate the 60% confidence region. If the peak's chemical shift in the HX dimension is outside of the 60%

-41-

confident region (using common sample statistics methods),  
remove it from the list of possible assignments (flag).

Step 4: Supplement U based on chemical shift (unambiguous) with noise filter.

5

Noise filter: Basic idea is that real peaks have:

- intensity > 0.05% of the highest intensity of real peaks
- tighter match tolerance to chemical shift list than used in Step 1 (Simple Match)

10

Highest intensity of real peaks – what is real peaks? Use the highest intensity of intra peaks.

T-type assignments

Step 5: Define B-type matches. subset of A-type matches for each spectra.

The B-type matches are defined as follows (by default):

For a given peak, order the A-type matches based on the size of the match value (MV), which is computed as follows:

15

$$MV = \min(\Delta HX + \Delta X/10 + \Delta H)$$

$$\text{where: } \Delta H = H_{\text{obs}} - H_{\text{DCSL}}$$

$$\Delta HX = HX_{\text{obs}} - HX_{\text{DCSL}}$$

$$\Delta X = X_{\text{obs}} - X_{\text{DCSL}}$$

20

and  $H_{\text{DCSL}}$ ,  $HX_{\text{DCSL}}$ , and  $X_{\text{DCSL}}$  are the sets of dynamically locally referenced values (DLRV) for the H, HX and X dimensions, respectively. Choose all possible matches with:  $\gamma \leq 0.01$ , where  $\gamma = |MV - (\Delta HX + \Delta X/10 + \Delta H)|$ .

Step 6: Use Contact Frequency (CF) of E to assign B-type matches to U set

25

\* Not for 2D spectra

- Create contact bin from all E's
- If element in B is in contact bin, Assign to U
- T-type assignment

Step 7: Use SYM (Symmetry Property) to assign B-type matches to U

30

\* Not for 2D spectra

If peak in B has another symmetry peak in B, Assign both to U, as T-type assignments



-42-

Step 8: Use HP-CORE to assign B-type matches to U

\* Not for 2D spectra

HP-CORE: Predicted Buried Residue

- 5
  - Create HP-CORE contact bin from all B's
    - HP-CORE to HP-CORE
    - not in the same secondary segment
  - If CF of the HP-CORE contact bin  $> N$ , assign all peaks in this bin to U. as T-type assignments.  $N$  is heuristic value that should scale with the number of NOESY spectra available, a typical value of  $N$  is 2.
- 10
  - If element in B is in contact bin, Assign to U
  - T-type assignment

Step 9: Compute 3D structure

O: Order Parameter

- 15
  - 0.8 (cycle 1), 0.7 (cycle 2), 0.6, (cycle 3), 0.5 (cycle 4)
  - 1. Calibration
    - D-type: distance is derived from its intensity
    - T-type: distance = 5.0 Å
- 20
  - 2. Run Structure Calculation Software
  - 3. Select 10 best, from family of 50 3D structures:
    - Compute:  $S(\phi)$ ,  $S(\varphi)$ ,  $\sigma(i,j)$  matrix, bb rmsd (exclude record with  $S(\phi) < 0.7$  and  $S(\varphi) < 0.7$ )
    - if bb rmsd is too large, STOP
    - if bb rmsd is  $< 1$  Å, go to step 12
- 25
  - 4. If has progress, go to step 10
  - 5. If no more progress, decrease O (next cycle). Identify disordered regions – order(i,j), from O
    - If  $(\langle S - O \rangle \geq 0 \ \& \ \sigma(i,j) - 2/O \leq 0)$
    - Order (i,j) = 1 (ordered)
    - Else Order (i,j) = 0 (disordered)
- 30

-43-

Example:

Cycle1:  $O = 0.8$ ,  $2/O = 2.5$ Cycle2:  $O = 0.7$ ,  $2/O = 2.85$ Cycle3:  $O = 0.6$ ,  $2/O = 3.33$ 

5

Cycle4:  $O = 0.5$ ,  $2/O = 4$ 

Step 10: Validation – remove from U list that consistently violated NOE assignments

V: Violation Parameter

Assumption: if  $> V$ , for sure, it is wrong assignments

10

If  $\text{order}(i,j) = 1$ ,  $V = 1$ ,

If  $\text{order}(i,j) = 0$ ,  $V = 2$

If  $\text{vmin}(i,j) > V$

- T-type: Delete it from the possible assignment list
- D-type: Downgrade to T-type assignment, and assign alternate assignments of  $<d> < 5 \text{ \AA}$  also as T-type assignments
- If a peak has more than one T-type assignments,  
If only one that is not violated, make it as D-type assignments

15

Step 11: Identify expected peaks that are consistent with 3D structure, put in U set.

20

D: Distance Cutoff

Assumption: If in ordered region, and  $> D$ , for sure, that is impossible to be a right assignment

If  $(\text{order}(i,j) = 1)$

$D = 5 + \text{rmsd} * 2$  and  $D_{\text{min}} = 5.5 \text{ \AA}$

25

N: Number of possible assignments left and put in U.

If  $\text{rmsd} > 2$ ,  $N \leq 2$ . If  $\text{rmsd} > 1$ ,  $N \leq 3$ ,

Rest,  $N \leq 4$ .

Pruning A list:

30

- Remove possible assignment with  $\text{dmn}(i,j) > D$  in ordered region
- If N possible assignment left, put in U as T-type assignments

Step 12: Back calculate all possible NOE' that are expected from the structure. Output any predicted assignments not in U or A list and peaks still in A list.

## Output:

For each cycle: Contact Map (assignment, structure(, Connectivity Map, Structures, Assignments (ordered by intra, seq, mid, long range),  $S(\phi)$ ,  $S(\varphi)$ ,  $\sigma(i,j)$  matrix, bb rmsd

5

## Overview:

- Number of Assignments for each assignment step
- Table    #Total NOE    #U(D+T)    #A    #Noise
- Noise Peak List
- A-type matches List

10

It will be apparent to those skilled in the art that various modifications may be made in the present invention without departing from the spirit and scope of the present invention. It will be additionally apparent to those skilled in the art that the basic construction of the present invention is intended to cover any variations, uses or adaptations of the invention following. in general, the principle of the invention and

15

including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto, rather than the specific embodiments which have been presented as examples.

**WHAT IS CLAIMED IS:**

1. A high-throughput method for determining a biochemical function of a protein or polypeptide domain of unknown function comprising:
  - (A) identifying a putative polypeptide domain that properly folds into a stable polypeptide domain. said stable polypeptide having a defined three dimensional structure;
  - (B) determining three dimensional structure of the stable polypeptide domain from an automated analysis of NMR spectrometer spectra of said polypeptide domain, wherein said automated analysis is conducted by a NOESY\_Assign process;
  - (C) comparing the determined three dimensional structure of the stable polypeptide domain to known three-dimensional structures in a protein data bank, wherein said comparison identifies known structures within said protein data bank that are homologous to the determined three dimensional structure; and
  - (D) correlating a biochemical function corresponding to the identified homologous structure to a biochemical function for the stable polypeptide domain.
2. The method according to claim 1, further comprising the prestep of parsing a target polynucleotide into at least one putative polypeptide domain.
3. The method according to claim 2, wherein said parsing is performed by a first computer algorithm, wherein said first computer algorithm is selected from the group consisting of a computer algorithm capable of determining exon phase boundaries of a polynucleotide, and a computer algorithm capable of determining interdomain boundaries encoded in a polynucleotide.
4. The method of claim 3, further comprising a computer algorithm that compares the putative polypeptide domain sequence with known domain sequences stored within a database.
5. The method of claim 1, wherein said NMR spectra are analyzed by a second computer algorithm that automatically assigns resonance assignments to the polypeptide sequence.

-46-

6. The method of claim 1, wherein said identification of said stable polypeptide domain comprises measuring a time course of amide hydrogen-deuterium exchange.
7. The method of claim 1, wherein prior to step (B), said stable polypeptide domain is optimally solubilized, said optimum solubilization comprising:
- i) preparing an array of microdialysis buttons, wherein each of said microdialysis buttons contains at least 1  $\mu$ l of an approximately 1mM solution of said stable polypeptide domain;
  - ii) dialyzing each member of said array of microdialysis buttons against a different dialysis buffer;
  - iii) analyzing each of said dialyzed microdialysis buttons to determine whether said stable polypeptide domain has remained soluble; and
  - iv) selecting the polypeptide domain having optimum solubility characteristics for NMR spectroscopy.
8. The method of claim 1, wherein said comparison of said determined three dimensional structure to said known three-dimensional structures in the protein data bank is performed by a third computer algorithm that is capable of determining 3D structure homology between said determined three dimensional structure and a member of said PDB.
9. The method according to claim 11, wherein said third computer algorithm is selected from the group consisting of DALI, CATH and VAST.
10. The method of claim 1, wherein said protein data bank is Protein Data Base ("PDB").
11. The method of claim 4, wherein said database contains domain sequence information of known and determined domain sequences.
12. An integrated system for rapid determination of a biochemical function of a protein or protein domain of unknown function:
- (A) a first computer algorithm capable of parsing said target polynucleotide into at least one putative domain encoding region;
  - (B) a designated lab for expressing said putative domain;

-47-

- 5 (C) an NMR spectrometer for determining individual spin resonances of amino acids of said putative domain;
- (D) a data collection device capable of collecting NMR spectral data, wherein said data collection device is operatively coupled to said NMR spectrometer;
- (E) at least one computer;
- (F) a second computer algorithm capable of assigning individual spin resonances to individual amino acids of a polypeptide;
- 10 (G) a third computer algorithm capable of determining tertiary structure of a polypeptide, wherein said polypeptide has had resonances assigned to individual amino acids of said polypeptide;
- (H) a database, wherein stored within said database is information about the structure and function of known proteins and determined proteins; and
- 15 (I) a fourth computer algorithm capable of determining 3D structure homology between the determined three-dimensional structure of a polypeptide of unknown function to three-dimensional structure of a protein of known function, wherein said protein of known structure is stored within said protein database, wherein said fourth computer algorithm determines said structure by an automated NOESY\_Assign process.
- 20
13. A high-throughput method for determining a biochemical function of a polypeptide of unknown function encoded by a target polynucleotide comprising the steps:
- 25 (A) identifying at least one putative polypeptide domain encoding region of the target polynucleotide ("parsing");
- (B) expressing said putative polypeptide domain;
- (C) determining whether said expressed putative polypeptide domain forms a stable polypeptide domain having a defined three dimensional structure ("trapping");
- 30 (D) determining the three dimensional structure of the stable polypeptide domain by an automated NOESY\_Assign process;
- (E) comparing the determined three dimensional structure of the stable polypeptide domain to known three dimensional structures in a Protein

-48-

Data Bank to determine whether any such known structures are homologous to the determined structure; and

- (F) correlating a biochemical function corresponding to the homologous structure to a biochemical function for the stable polypeptide domain.

09744002-080201




FIG.1



2/24




FIG. 2A




FIG. 2B

3/24




FIG.3

4/24




FIG.4






FIG.5

5/24

FIG. 6



6/24



7/24




FIG.8A




FIG.8B

9/24

## NOESY\_ASSIGN PROCESS






FIG.9



10/24



11/24



Automated Structure Analysis      Manual Structure Analysis

FIG.10B

12/24

Zdom: Automated Assignment Analysis




FIG.11

13/24

## Zdom: AUTOMATED STRUCTURE ANALYSIS




FIG.12




FIG.13

15/24

## Zdom: Manual Assignment Analysis




FIG.14

16/24

Zdom: MANUAL STRUCTURE ANALYSIS




FIG.15





FIG.16




18/24

CspA



AUTOMATED STRUCTURE ANALYSIS



MANUAL STRUCTURE ANALYSIS

FIG.17

19/24

## Cspa: Automated Assignment Analysis




FIG.18

20/24

## Cspa: AUTOMATED STRUCTURE ANALYSIS




FIG.19

Cspa: AUTOMATED ANALYSIS--CONNECTIVITY MAP





FIG.20

22/24

## Cspa: Manual Assignment Analysis




FIG.21

23/24

## Cspa: MANUAL STRUCTURE ANALYSIS




FIG.22

FOI2080" 2004/4/60

24/24

Cspa: MANUAL ANALYSIS-CONNECTIVITY MAP





FIG.23

Docket No.

RU-011S

**Declaration and Power of Attorney For Patent Application****English Language Declaration**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

☐ LINKING GENE SEQUENCE TO GENE FUNCTION BY THREE DIMENSIONAL (3D)

☐ PROTEIN STRUCTURE DETERMINATION

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on July 21, 1999 as United States Application No. or PCT International

Application Number PCT/US99/16417

and was amended on \_\_\_\_\_

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐



07/18/01 WED 09:35 FAX 9568101454

LAW OFFICES

0004

Page 3 of 4

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)



26259

PATENT, TRADEMARK OFFICE

Send Correspondence to:

Direct Telephone Calls to: (name and telephone number)

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor

Stephen Anderson

Sole or first inventor's signature

Stephen Anderson

Date

1 Aug. '01

Residence

Princeton, New Jersey NJ

Citizenship

US

Post Office Address

158 Springdale Road

Princeton, New Jersey 08540

Full name of second inventor, if any

Gaetano Montefione

Second inventor's signature

Date

Residence

Highland Park, New Jersey

Citizenship

US

Post Office Address

127 North 5th Avenue

Highland Park, New Jersey 08904

07/18/01 WED 09:35 FAX 8568101454

LAW OFFICES

0004

Page 3 of 4

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)



26259

PATENT, TRADEMARK OFFICE

Send Correspondence to:

Direct Telephone Calls to: (name and telephone number)

Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

Full name of sole or first inventor <b>Stephen Anderson</b>	
Sole or first inventor's signature	Date
Residence <b>Princeton, New Jersey</b>	
Citizenship <b>US</b>	
Post Office Address <b>158 Springdale Road</b>	
<b>Princeton, New Jersey</b>	

Full name of second inventor, if any <b>Gaetano Montellone</b>		Date <b>7/28/01</b>
Second inventor's signature <i>Gaetano Montellone</i>		
Residence <b>Highland Park, New Jersey NJ</b>		
Citizenship <b>US</b>		
Post Office Address <b>127 North 5th Avenue</b>		
<b>Highland Park, New Jersey 08904</b>		

7-30-01: 4:34PM;OCLTT, RUTGERS UNIV

;7324455670

# 8/ 8

Jul 30 01 04:23p

Montelione CABM

1 732 235 5633

p.2

7-30-01: 3:50PM;OCLTT, RUTGERS UNIV

;7324455670

# 1/ 1

07/18/01 WED 09:35 FAX 8568101454

LAW OFFICES

005

Page 4 of 4

300  
Full name of third inventor, if any

Yuanpeng Huang

Third inventor's signature

Residence  
Edison, New Jersey NJ

Date

7/30/01

Citizenship  
US

Post Office Address  
168 Linda Lane

Edison, New Jersey 08854-8010

Full name of fourth inventor, if any

Fourth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of fifth inventor, if any

Fifth inventor's signature

Date

Residence

Citizenship

Post Office Address

Full name of sixth inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address